+

US20020173524A1 - Modulation of CCR4 function - Google Patents

Modulation of CCR4 function Download PDF

Info

Publication number
US20020173524A1
US20020173524A1 US09/975,566 US97556601A US2002173524A1 US 20020173524 A1 US20020173524 A1 US 20020173524A1 US 97556601 A US97556601 A US 97556601A US 2002173524 A1 US2002173524 A1 US 2002173524A1
Authority
US
United States
Prior art keywords
alkyl
compound
substituted
group
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/975,566
Inventor
Tassie Collins
Daniel Dairaghi
Hossen Mahmud
Brian McMaster
Julio Medina
Thomas Schall
Feng Xu
Xuemei Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen SF LLC
Chemocentryx Inc
Original Assignee
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc filed Critical Tularik Inc
Priority to US09/975,566 priority Critical patent/US20020173524A1/en
Publication of US20020173524A1 publication Critical patent/US20020173524A1/en
Assigned to TULARIK, INC. reassignment TULARIK, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MAHMUD, HOSSEN, MEDINA, JULIO, XU, FENG, WANG, XUEMEI, COLLINS, TASSIE
Assigned to CHEMOCENTRYX, INC. reassignment CHEMOCENTRYX, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHALL, THOMAS, DAIRAGHI, DANIEL, MCMASTER, BRIAN
Priority to US10/654,112 priority patent/US7262204B2/en
Assigned to AMGEN SF, LLC reassignment AMGEN SF, LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: ARROW ACQUISITION, LLC
Assigned to ARROW ACQUISITION, LLC reassignment ARROW ACQUISITION, LLC MERGER (SEE DOCUMENT FOR DETAILS). Assignors: TULARIK INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • Chemokines are chemotactic cytokines that are released by a wide variety of cells to attract macrophages, T cells, eosinophils, basophils and neutrophils to sites of inflammation (reviewed in Schall, Cytokine, 3:165-183 (1991), Schall, et al, Curr. Opin. Immunol. 6:865-873 (1994) and Murphy, Rev. Immun., 12:593-633 (1994)).
  • chemokines in addition to stimulating chemotaxis, other changes can be selectively induced by chemokines in responsive cells, including changes in cell shape, transient rises in the concentration of intracellular free calcium ions ([Ca 2+]) i , granule exocytosis, integrin upregulation, formation of bioactive lipids (e.g., leukotrienes) and respiratory burst, associated with leukocyte activation.
  • the chemokines are early triggers of the inflammatory response, causing inflammatory mediator release, chemotaxis and extravasation to sites of infection or inflammation.
  • CXC chemokines
  • the ⁇ -chemokines such as interleukin-8 (IL-8), melanoma growth stimulatory activity protein (MGSA), and stromal cell derived factor 1 (SDF-1) are chemotactic primarily for neutrophils and lymphocytes, whereas ⁇ -chemokines, such as RANTES, MIP-1 ⁇ , MIP-1 ⁇ , monocyte chemotactic protein-1 (MCP-1), MCP-2, MCP-3 and eotaxin are chemotactic for macrophages, T-cells, eosinophils and basophils (Deng, et al., Nature, 381:661-666 (1996)).
  • IL-8 interleukin-8
  • MGSA melanoma growth stimulatory activity protein
  • SDF-1 stromal cell derived factor 1
  • the C chemokine lymphotactin shows specificity for lymphocytes (Kelner, et al., Science, 266:1395-1399 (1994)) while the CX 3 C chemokine fractalkine shows specificity for lymphocytes and monocytes (Bazan, et al., Nature, 385:640-644 (1997).
  • Chemokines bind to specific cell-surface receptors belonging to the family of G-protein-coupled seven-transmembrane-domain proteins (reviewed in Horuk, Trends Pharm. Sci. 15:159-165 (1994)) which are termed “chemokine receptors.” On binding their cognate ligands, chemokine receptors transduce an intracellular signal through the associated heterotrimeric G protein, resulting in a rapid increase in intracellular calcium concentration.
  • CCR1 or “CKR-1” or “CC-CKR-1”
  • CC-CKR-1 chemokine receptors that bind or respond to ⁇ -chemokines with the following characteristic pattern: CCR1 (or “CKR-1” or “CC-CKR-1”) to MIP-1 ⁇ , MIP-1 ⁇ , MCP-3, RANTES (Ben-Barruch, et al., J. Biol.
  • CCR2A and CCR2B (or “CKR-2A”/“CKR-2A” or “CC-CKR-2A”/“CC-CKR2A”) to MCP-1, MCP-3, MCP-4; CCR3 (or “CKR-3” or “CC-CKR-3”) to eotaxin, RANTES, MCP; (Ponath, et al., J. Exp.
  • CCR4 also referred to as “CKR-4”,“CC-CKR-4” or “CMKBR4”
  • CCR4 also referred to as “CKR-4”,“CC-CKR-4” or “CMKBR4”
  • CCR5 or “CKR-5” or “CC-CKR-5”
  • CCR6 to MIP-3 alpha
  • CCR7 to MIP-3 beta and 6Ckine (Campbell, et al., J.
  • Chemokine receptors such as CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CX 3 CR1 and XCR1 have been implicated as being important mediators of inflammatory and immunoregulatory disorders and diseases, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis.
  • the CCR4 chemokine receptor is expressed primarily in peripheral blood T lymphocytes. CCR4 is involved in T lymphocyte homing to the skin and lungs (see, e.g., Campbell et al. (1999) Nature 400:776-780, Gonzalo et al. (1999) J. Immunol. 163:403-411, Lloyd et al. (2000) J. Exp. Med. 191:265-273, Kawasaki et al. (2001) J. Immunol. 166:2055-2062).
  • the present invention is directed to compounds which are modulators of CCR4 chemokine receptor function and are useful in the prevention or treatment of inflammatory conditions and diseases such as allergic diseases, psoriasis, atopic dermatitis and asthma.
  • the invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases in which CCR4 chemokine receptors are involved.
  • the present invention provides compounds having the general formula (I):
  • W is selected from aryl, heteroaryl, (C 1 -C 8 )alkyl, heteroalkyl, cycloalkyl and heterocycloalkyl;
  • X is selected from N(R 5 ), S, O, C(R 3 ) ⁇ C(R 4 ), N ⁇ C(R 4 ), and optionally, when Z is N, X can be C(R 6 )(R 7 );
  • Y is selected from a bond, N(R 5 ), N(R 5 )-(C 1 -C 8 )alkylene, O, S and S(O) n , wherein the integer n is 1 or 2; and Z is selected from N and C(R 8 ).
  • R 1 and R 2 are independently selected from H, halogen, CN, CO 2 R′, CONR′R′′, (C 1 -C 8 )alkyl, heteroalkyl, aryl, heteroaryl, N(R 6 )(R 7 ), OR 9 and optionally, R 1 and R 2 combine to form a 5- to 8-membered ring containing from 0 to 3 heteroatoms selected from N, O and S, wherein R′ and R′′ are independently selected from H, (C 1 -C 8 )alkyl and aryl. When R′ and R′′ are attached to nitrogen, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring.
  • R 3 , R 4 and R 8 are independently selected from H, halogen, CN, OH, (C 1 -C 8 )alkyl, heteroalkyl, aryl, heteroaryl, O(C 1 -C 8 )alkyl, N(R 6 )(R 7 ) and OR 9 ;
  • R 5 is selected from H, (C 1 -C 8 )alkyl, heteroalkyl, aryl and heteroaryl;
  • R 6 and R 7 are independently selected from H, (C 1 -C 8 )alkyl, heteroalkyl, aryl and heteroaryl;
  • R 9 is selected from (C 1 -C 8 )alkyl, heteroalkyl and haloalkyl; with the provisos that R 1 is other than phenyl, when W is phenyl or unsubstituted naphthyl, X is S, Y is NH, and Z is N; and R 2 is other than H when W is unsubstit
  • a number of embodiments are preferred within the above formula.
  • Z is N; wherein X is S; wherein Y is N(R 5 ); wherein Z is N, X is S and Y is N(R 5 ); wherein W is aryl or heteroaryl; wherein W is aryl or heteroaryl and aryl is phenyl or naphthyl; wherein W is aryl or heteroaryl and heteroaryl is pyridyl or quinolyl; wherein R 1 and R 2 are independently H or (C 1 -C 8 )alkyl; wherein R 1 and R 2 combine to form a fused 6-membered aryl or heteroaryl ring; wherein W is aryl or heteroaryl, X is S, Y is N(R 5 ), Z is N, and R 1 and R 2 are independently H or (C 1 -C 8 )alkyl; wherein W is aryl or heteroaryl; X is S, Y is N(R 5 ),
  • the compound is represented by formula (Ia):
  • the present invention provides a composition comprising a pharmaceutically acceptable carrier and a compound of formula I as provided above, or a compound of formula I wherein R 1 is phenyl, when W is phenyl or unsubstituted naphthyl, X is S, Y is NH, and Z is N; and R 2 is H when W is unsubstituted phenyl, X is S, Y is NH, Z is N and R 1 is (C 1 -C 8 )alkyl.
  • the present invention provides a method of treating a CCR4-mediated condition or disease, comprising administering to a subject in need of such treatment, a therapeutically effective amount of a composition as described herein.
  • the CCR4-mediated condition or disease is selected from an allergic disease, psoriasis, atopic dermatitis and asthma; the CCR4-mediated condition or disease is an allergic disease; the CCR4-mediated condition or disease is an allergic disease and the allergic disease is selected from systemic anaphylaxis, hypersensitivity responses, drug allergies, insect sting allergies and food allergies; the CCR4-mediated condition or disease is psoriasis; the CCR4-mediated condition or disease is atopic dermatitis; the CCR4-mediated condition or disease is asthma; the CCR4-mediated condition or disease is an allergic condition and the compound is used alone or in combination with at least one therapeutic agent wherein the therapeutic agent is an antihistamine; the CCR4-mediated condition or disease is psoriasis and the compound is used alone or in combination with at least one therapeutic agent selected from a corticosteroid, a lubricant, a keratolytic agent
  • the present invention provides a a method of modulating CCR4 function in a cell, comprising contacting the cell with a therapeutically effective amount of a compound of formula I.
  • the present invention provides a method for modulating CCR4 function, comprising contacting a CCR4 protein with a therapeutically effective amount of a compound of formula I.
  • Ar 1 and Ar 2 each independently represent a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a substituted or unsubstituted fused aryl-heterocyclic ring system.
  • the letter X represents a linking group selected from —N(R)—, —C(O)S—, —CH ⁇ CHSO 2 — and —SO 2 N(R)— wherein R is H or a substituted or unsubstituted (C 1 -C 8 )alkyl group.
  • the linking group can be in either orientation relative to the Ar 1 and Ar 2 moieties.
  • the above general formula is meant to include both Ar 1 —SO 2 —NH—Ar 2 and Ar 1 —NH—SO 2 —Ar 2 .
  • These compounds are useful in compositions and methods for the treatment of CCR4-mediated conditions or diseases, particularly those recited above with reference to compounds of formula I.
  • FIG. 1 is a graph showing the results of a CCR4/TARC competition assay using compound 1.1.
  • FIG. 2 is a graph showing the results of a CCR4/TARC competition assay using compound 1.2.
  • FIG. 3 is a graph showing the results of a CCR4/TARC competition assay using compound 1.3.
  • FIG. 4 illustrates the results achieved with compound 1.2 in CEM migration assays with CCR4 and TARC.
  • FIG. 5 illustrates the effect of compound 1.3 on CEM calcium response.
  • FIG. 6 illustrates the effect of compound 1.2 on CEM calcium response.
  • alkyl by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (i.e. C 1 -C 10 means one to ten carbons).
  • saturated hydrocarbon radicals include groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
  • An unsaturated alkyl group is one having one or more double bonds or triple bonds.
  • alkyl groups examples include vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers.
  • alkyl unless otherwise noted, is also meant to include those derivatives of alkyl defined in more detail below as “heteroalkyl.” Alkyl groups which are limited to hydrocarbon groups are termed “homoalkyl”.
  • alkylene by itself or as part of another substituent means a divalent radical derived from an alkane, as exemplified by —CH 2 CH 2 CH 2 CH 2 —, and further includes those groups described below as “heteroalkylene.”
  • an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention.
  • a “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.
  • alkoxy alkylamino and “alkylthio” (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively.
  • heteroalkyl by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and from one to three heteroatoms selected from the group consisting of O, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized.
  • the heteroatom(s) O, N and S may be placed at any interior position of the heteroalkyl group.
  • the heteroatom Si may be placed at any position of the heteroalkyl group, including the position at which the alkyl group is attached to the remainder of the molecule.
  • Examples include —CH 2 —CH 2 —O—CH 3 , —CH 2 —CH 2 —NH—CH 3 , —CH 2 —CH 2 —N(CH 3 )—CH 3 , —CH 2 —S—CH 2 —CH 3 , —CH 2 —CH 2 , —S(O)—CH 3 , —CH 2 —CH 2 —S(O) 2 —CH 3 , —CH ⁇ CH—O—CH 3 , —Si(CH 3 ) 3 , —CH 2 —CH ⁇ N—OCH 3 , and —CH ⁇ CH—N(CH 3 )—CH 3 .
  • heteroalkylene by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified by —CH 2 —CH 2 —S—CH 2 CH 2 — and —CH 2 —S—CH 2 —CH 2 —NH—CH 2 —.
  • heteroalkylene groups heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied.
  • cycloalkyl and “heterocycloalkyl”, by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl”, respectively. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like.
  • heterocycloalkyl examples include 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-moorpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.
  • halo or “halogen,” by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as “haloalkyl,” are meant to include monohaloalkyl and polyhaloalkyl. For example, the term “halo(C 1 -C 4 )alkyl” is mean to include trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
  • aryl means, unless otherwise stated, a polyunsaturated, typically aromatic, hydrocarbon substituent which can be a single ring or multiple rings (up to three rings) which are fused together or linked covalently.
  • heteroaryl refers to aryl groups (or rings) that contain from zero to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quatemized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom.
  • Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinoly
  • aryl when used in combination with other terms (e.g., aryloxy, arylthioxy, arylalkyl) includes both aryl and heteroaryl rings as defined above.
  • arylalkyl is meant to include those radicals in which an aryl group is attached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl and the like) including those alkyl groups in which a carbon atom (e.g., a methylene group) has been replaced by, for example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naphthyloxy)propyl, and the like).
  • alkyl group e.g., benzyl, phenethyl, pyridylmethyl and the like
  • an oxygen atom e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naph
  • Substituents for the alkyl and heteroalkyl radicals can be a variety of groups selected from: —OR′, ⁇ O, ⁇ NR′, ⁇ N—OR′, —NR′R′′, —SR′, -halogen, —SiR′R′′R′′′, —OC(O)R′, —C(O)R′, —CO 2 R′, —CONR′R′′, —OC(O)NR′R′′, —NR′′C(O)R′, —NR′—C(O)NR′′R′′′, —NR′′C(O) 2 R′, —NH—C(NH 2 ) ⁇ NH, —NR′C(NH 2 ) ⁇ NH
  • R′, R′′ and R′′′ each independently refer to hydrogen, unsubstituted (C 1 -C 8 )alkyl and heteroalkyl, unsubstituted aryl, aryl substituted with 1-3 halogens, unsubstituted alkyl, alkoxy or thioalkoxy groups, or aryl-(C 1 -C 4 )alkyl groups.
  • R′ and R′′ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring.
  • —NR′R′′ is meant to include 1-pyrrolidinyl and 4-morpholinyl.
  • alkyl is meant to include groups such as haloalkyl (e.g., —CF 3 and —CH 2 CF 3 ) and acyl (e.g., —C(O)CH 3 , —C(O)CF 3 , —C(O)CH 2 OCH 3 , and the like).
  • haloalkyl e.g., —CF 3 and —CH 2 CF 3
  • acyl e.g., —C(O)CH 3 , —C(O)CF 3 , —C(O)CH 2 OCH 3 , and the like.
  • substituents for the aryl and heteroaryl groups are varied and are selected from: -halogen, —OR′, —OC(O)R′, —NR′R′′, —SR′, —R′, —CN, —NO 2 , —CO 2 R′, —CONR′R′′, —C(O)R′, —OC(O)NR′R′′, —NR′′C(O)R′, —NR′′C(O) 2 R′, , —NR′—C(O)NR′′R′′′, —NH—C(NH 2 ) ⁇ NH, —NR′C(NH 2 ) ⁇ NH, —NH—C(NH 2 ) ⁇ NR′, —S(O)R′, —S(O) 2 R′, —S(O) 2 NR′R′′, —N 3 , —CH(Ph) 2 , perfluoro(C 1 -C 4 )alkoxy, and per
  • Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula —T—C(O)—(CH 2 ) q —U—, wherein T and U are independently —NH—, —O—, —CH 2 — or a single bond, and q is an integer of from 0 to 2.
  • two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula —A—(CH 2 ) r —B—, wherein A and B are independently —CH 2 —, —O—, —NH—, —S—, —S(O)—, —S(O) 2 —, —S(O) 2 NR′— or a single bond, and r is an integer of from 1 to 3.
  • One of the single bonds of the new ring so formed may optionally be replaced with a double bond.
  • two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula —(CH 2 ) s —X—(CH 2 ) t —, where s and t are independently integers of from 0 to 3, and X is —O—, —NR′—, —S—, —S(O)—, —S(O) 2 —, or —S(O) 2 NR′—.
  • the substituent R′ in —NR′— and —S(O) 2 NR′— is selected from hydrogen or unsubstituted (C 1 -C 6 ) alkyl.
  • heteroatom is meant to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si).
  • salts are meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
  • base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
  • pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
  • acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
  • Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like.
  • inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like,
  • salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge, S. M., et al, “Pharmaceutical Salts”, Journal of Pharmaceutical Science, 1977, 66, 1-19).
  • Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
  • the neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
  • the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
  • the present invention provides compounds which are in a prodrug form.
  • Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention.
  • prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
  • Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
  • Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are all intended to be encompassed within the scope of the present invention.
  • the compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
  • the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.
  • Chemokine receptors are attractive targets for the development of antiinflammatory agents.
  • Small molecule antagonists of chemokine receptors e.g., CC chemokine receptors, however, are not widely known.
  • U.S. Pat. No. 6,207,665 to Hesselgesser et al. describes piperazine derivatives as CCR1 antagonists and is hereby incorporated by reference.
  • the present invention is directed to compounds, compositions and methods useful in the modulation of chemokine receptor function, particularly CCR4 function. Accordingly, the compounds of the present invention are compounds which inhibit at least one function or characteristic of a mammalian CCR4 protein, for example, a human CCR4 protein.
  • a compound to inhibit the function of CCR4 can be demonstrated in a binding assay (e.g., ligand binding or agonist binding), a signalling assay (e.g., activation of a mammalian G protein, induction of rapid and transient increase in the concentration of cytosolic free calcium), and/or cellular response assay (e.g., stimulation of chemotaxis, exocytosis or inflammatory mediator release by leukocytes).
  • a binding assay e.g., ligand binding or agonist binding
  • a signalling assay e.g., activation of a mammalian G protein, induction of rapid and transient increase in the concentration of cytosolic free calcium
  • cellular response assay e.g., stimulation of chemotaxis, exocytosis or inflammatory mediator release by leukocytes.
  • the present invention is directed to compounds, compositions and methods useful in the modulation of chemokine receptor activity, particularly CCR4. Accordingly, the compounds of the present invention are those which inhibit at least one function or characteristic of a mammalian CCR4 protein, for example, a human CCR4 protein.
  • a binding assay e.g., ligand binding or promotor binding
  • a signalling assay e.g., activation of a mammalian G protein, induction of rapid and transient increase in the concentration of cytosolic free calcium
  • cellular response function e.g., stimulation of chemotaxis, exocytosis or inflammatory mediator release by leukocytes.
  • the present invention provides compounds having antiinflammatory or anti-immunoregulatory activity.
  • the compounds of the invention are thought to interfere with inappropriate T-cell trafficking by specifically modulating or inhibiting a chemokine receptor function.
  • Chemokine receptors are integral membrane proteins which interact with an extracellular ligand, or chemokine, and mediate a cellular response to the chemokine, e.g., chemotaxis, increased intracellular calcium ion concentration. Therefore, inhibition of a chemokine receptor function, e.g., interference with a chemokine receptor-ligand interaction, will inhibit a chemokine receptor-mediated response and treat or prevent a chemokine receptor-mediated condition or disease.
  • the compounds provided herein interfere with the interaction between a chemokine receptor and one or more cognate ligands.
  • the compounds interfere with the interaction between CCR4 and a CCR4 ligand, e.g., TARC, MDC, etc.
  • Compounds contemplated by the invention include, but are not limited to, the exemplary compounds provided herein.
  • W is selected from aryl, heteroaryl, (C 1 -C 8 )alkyl, heteroalkyl, cycloalkyl and heterocycloalkyl;
  • X is selected from N(R 5 ), S, O, C(R 3 ) ⁇ C(R 4 ), N ⁇ C(R 4 ), and optionally, when Z is N, X can be C(R 6 )(R 7 );
  • Y is selected from a bond, N(R 5 ), N(R 5 )-(C 1 -C 8 )alkylene, O, S and S(O) n , wherein the integer n is 1 or 2; and Z is selected from N and C(R 8 ).
  • R 1 and R 2 are independently selected from H, halogen, CN, CO 2 R′, CONR′R′′, (C 1 -C 8 )alkyl, heteroalkyl, aryl, heteroaryl, N(R 6 )(R 7 ), OR 9 and optionally, R 1 and R 2 combine to form a 5- to 8-membered ring containing from 0 to 3 heteroatoms selected from N, O and S, wherein R′ and R′′ are independently selected from H, (C 1 -C 8 )alkyl and aryl. When R′ and R′′ are attached to nitrogen, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring.
  • R 3 , R 4 and R 8 are independently selected from H, halogen, CN, OH, (C 1 -C 8 )alkyl, heteroalkyl, aryl, heteroaryl, O(C 1 -C 8 )alkyl, N(R 6 )(R 7 ) and OR 9 ;
  • R 5 is selected from H, (C 1 -C 8 )alkyl, heteroalkyl, aryl and heteroaryl;
  • R 6 and R 7 are independently selected from H, (C 1 -C 8 )alkyl, heteroalkyl, aryl and heteroaryl;
  • R 9 is selected from (C 1 -C 8 )alkyl, heteroalkyl and haloalkyl; with the provisos that R 1 is other than phenyl, when W is phenyl or unsubstituted naphthyl, X is S, Y is NH, and Z is N; and R 2 is other than H when W is unsubstit
  • the ring system or “scaffold” is meant to include the following (including substituted versions thereof) wherein the “A” ring is selected from the following embodiments:
  • Z is N.
  • X is S.
  • Y is N(R 5 ).
  • Particularly preferred are those embodiments that combine each of these preferred groups. Accordingly, in one group of particularly preferred embodiments X is S, Y is N(R 5 ) and Z is N.
  • W is selected from aryl and heteroaryl. Particularly preferred are those embodiments in which aryl is phenyl or naphthyl. Other particularly preferred embodiments are those in which heteroaryl is pyridyl or quinolyl.
  • R 1 and R 2 are independently H or (C 1 -C 8 )alkyl. In still other separate, but preferred embodiments, R 1 and R 2 combine to form a fused 6-membered aryl or heteroaryl ring.
  • R 5 is most preferably H.
  • the compounds of the invention have the formula(I), wherein W is selected from substituted naphthyl, pyridyl quinolyl, (C 1 -C 8 )alkyl, heteroalkyl, cycloalkyl and heterocycloalkyl; X is selected from N(R 5 ), S, O, C(R 3 ) ⁇ C(R 4 ), N ⁇ C(R 4 ), and optionally, when Z is N, X can be C(R 6 )(R 7 ); Y is selected from a bond, N(R 5 ), N(R 5 )-(C 1 -C 8 )alkylene, 0, S and S(O) n , wherein the integer n is 1 or 2; and Z is selected from N and C(R 8 ).
  • R 1 and R 2 are independently selected from H, halogen, CN, CO 2 R′, CONR′R′′, (C 1 -C 8 )alkyl, heteroalkyl, aryl, heteroaryl, N(R 6 )(R 7 ), OR 9 and optionally, R 1 and R 2 combine to form a 5- to 8-membered ring containing from 0 to 3 heteroatoms selected from N, O and S, wherein R′ and R′′ are independently selected from H, (C 1 -C 8 )alkyl and aryl. When R′ and R′′ are attached to nitrogen, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring.
  • R 3 , R 4 and R 8 are independently selected from H, halogen, CN, OH, (C 1 -C 8 )alkyl, heteroalkyl, aryl, heteroaryl, O(C 1 -C 8 )alkyl, N(R 6 )(R 7 ) and OR 9 ;
  • R 5 is selected from H, (C 1 -C 8 )alkyl, heteroalkyl, aryl and heteroaryl;
  • R 6 and R 7 are independently selected from H, (C 1 -C 8 )alkyl, heteroalkyl, aryl and heteroaryl; and
  • R 9 is selected from (C 1 -C 8 )alkyl, heteroalkyl and haloalkyl.
  • a number of embodiments are particularly preferred within this group and are separately provided as those wherein Z is N; wherein X is S; wherein Y is N(R 5 ); wherein Z is N, X is S and Y is N(R 5 ); wherein W is substituted naphthyl; wherein W is pyridyl or quinolyl; wherein R 1 is other than phenyl; wherein R 1 and R 2 are independently H or (C 1 -C 8 )alkyl; wherein R 1 and R 2 combine to form a fused 6-membered aryl or heteroaryl ring; wherein W is substituted naphthyl, X is S, Y is N(R 5 ), Z is N, and R 1 and R 2 are independently H or (C 1 -C 8 )alkyl; wherein W is substituted naphthyl, X is S, Y is N(R 5 ), Z is N, and R 1 and R 2 are independently H or (C 1 -C 8
  • the A ring is a thiazole ring (see formula Ia).
  • W, Y, R 1 and R 2 have the meanings (and preferred groupings) provided above. Exemplary structures within this preferred group of embodiments are shown below.
  • compositions and methods for the treatment of CCR4-mediated conditions and diseases as described in more detail below.
  • present invention further includes aspects directed to pharmaceutical compositions and methods using compounds that are known, particularly those that are commercially available.
  • Exemplary commercially available compounds include: 4-(1,1 -dimethylethyl)-N-phenyl-2-thiazolamine, 4-methyl-N-phenyl-2-thiazolamine, 4-(1-methylethyl)-N-phenyl-2-thiazolamine, 4-dodecyl-N-phenyl-2-thiazolamine, 2-anilino-4-isobutyl-thiazole, and 2-anilino-4-methyl-thiazole picrate.
  • the present invention provides compositions that modulate CCR4 activity.
  • compositions will comprise a pharmaceutically acceptable excipient and a compound having the formula provided above as formula I:
  • W is selected from aryl, heteroaryl, (C 1 -C 8 )alkyl, heteroalkyl, cycloalkyl and heterocycloalkyl;
  • X is selected from N(R 5 ), S, O, C(R 3 ) ⁇ C(R 4 ), N ⁇ C(R 4 ), and optionally, when Z is N, X can be C(R 6 )(R 7 );
  • Y is selected from a bond, N(R 5 ), N(R 5 )-(C 1 -C 8 )alkylene, O, S and S(O) n , wherein the integer n is 1 or 2; and Z is selected from N and C(R 8 ).
  • R 1 and R 2 are independently selected from H, halogen, CN, CO 2 R′, CONR′R′′, (C 1 -C 8 )alkyl, heteroalkyl, aryl, heteroaryl, N(R 6 )(R 7 ), OR 9 and optionally, R 1 and R 2 combine to form a 5- to 8-membered ring containing from 0 to 3 heteroatoms selected from N, O and S, wherein R′ and R′′ are independently selected from H, (C 1 -C 8 )alkyl and aryl. When R′ and R′′ are attached to nitrogen, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring.
  • R 3 , R 4 and R 8 are independently selected from H, halogen, CN, OH, (C 1 -C 8 )alkyl, heteroalkyl, aryl, heteroaryl, O(C 1 -C 8 )alkyl, N(R 6 )(R 7 ) and OR 9 ;
  • R 5 is selected from H, (C 1 -C 8 )alkyl, heteroalkyl, aryl and heteroaryl;
  • R 6 and R 7 are independently selected from H, (C 1 -C 8 )alkyl, heteroalkyl, aryl and heteroaryl; and
  • R 9 is selected from (C 1 -C 8 )alkyl, heteroalkyl and haloalkyl.
  • Preferred compounds useful in the present compositions are those of formula I in which W is selected from substituted naphthyl, pyridyl quinolyl, (C 1 -C 8 )alkyl, heteroalkyl, cycloalkyl and heterocycloalkyl;
  • X is selected from N(R 5 ), S, O, C(R 3 ) ⁇ C(R 4 ), N ⁇ C(R 4 ), and optionally, when Z is N, X can be C(R 6 )(R 7 );
  • Y is selected from a bond, N(R 5 ), N(R 5 )-(C 1 -C 8 )alkylene, O, S and S(O) n , wherein the integer n is 1 or 2; and Z is selected from N and C(R 8 ).
  • R 1 and R 2 are independently selected from H, halogen, CN, CO 2 R′, CONR′R′′, (C 1 -C 8 )alkyl, heteroalkyl, aryl, heteroaryl, N(R 6 )(R 7 ), OR 9 and optionally, R 1 and R 2 combine to form a 5- to 8-membered ring containing from 0 to 3 heteroatoms selected from N, O and S, wherein R′ and R′′ are independently selected from H, (C 1 -C 8 )alkyl and aryl. When R′ and R′′ are attached to nitrogen, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring.
  • R 3 , R 4 and R 8 are independently selected from H, halogen, CN, OH, (C 1 -C 8 )alkyl, heteroalkyl, aryl, heteroaryl, O(C 1 -C 8 )alkyl, N(R 6 )(R 7 ) and OR 9 ;
  • R 5 is selected from H, (C 1 -C 8 ) alkyl, heteroalkyl, aryl and heteroaryl;
  • R 6 and R 7 are independently selected from H, (C 1 -C 8 )alkyl, heteroalkyl, aryl and heteroaryl; and
  • R 9 is selected from (C 1 -C 8 )alkyl, heteroalkyl and haloalkyl.
  • Ar 1 and Ar 2 each independently represent a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a substituted or unsubstituted fused aryl-heterocyclic ring system.
  • the letter X represents a linking group selected from the group consisting of —N(R)—, —C(O)S—, —CH ⁇ CHSO 2 — and —SO 2 N(R)— wherein R is H or a substituted or unsubstituted (C 1 -C 8 )alkyl group.
  • the linking group can be in either orientation relative to the Ar 1 and Ar 2 moieties.
  • the above general formula is meant to include both Ar 1 —SO 2 —NH—Ar 2 and Ar 1 —NH—SO 2 —Ar 2 .
  • Ar 1 is a substituted or unsubstituted heteroaryl group.
  • Ar 1 is a substituted or unsubstituted 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4 -pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinon
  • Ar 2 is a substituted or unsubstituted aryl group. More preferably, Ar 2 is a substituted or unsubstituted phenyl or naphthyl group.
  • Ar 2 is a substituted aryl group
  • Ar 2 is a substituted or unsubstituted phenyl or naphthyl group.
  • the substituted phenyl and napthyl groups will preferably have from 1 to 3 substituents independently selected from halogen, (C 1 -C 4 )haloalkyl, (C 1 -C 4 )haloalkoxy, nitro, cyano and (C 1 -C 4 )acyl.
  • Ar 1 and Ar 2 are each members independently selected from the group consisting of:
  • Ar 1 is selected from substituted or unsubstituted phenyl or 2-naphthyl and Ar 2 is selected from substituted or unsubstituted
  • the compounds used in the present compositions are selected from:
  • a number of compounds useful as modulators of CCR4 signalling can be obtained from commercial sources such as Maybridge Chemical Co. and Aldrich Chemical Co. (Milwaukee, Wis., USA).
  • an aryl (or heteroaryl) sulfonyl chloride i can be combined with a suitable aryl (or heteroaryl) amine ii to provide the target sulfonamides iii.
  • the starting sulfonyl chlorides are typically prepared in one step from a sulfonic acid using a chlorinating agent such as POCl 3 or SOCl 2 .
  • starting arylamines ii are available from commercial sources or can be prepared in one step from the corresponding nitroaryl compounds.
  • compositions for modulating chemokine receptor activity in humans and animals will typically contain a pharmaceutical carrier or diluent.
  • Modulation of chemokine receptor activity is intended to encompass antagonism, agonism, partial antagonism and/or partial agonism of the activity associated with a particular chemokine receptor, preferably the CCR4 receptor.
  • composition as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • compositions for the administration of the compounds of this invention may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients.
  • the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.
  • the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases.
  • compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions. Such compositions may contain one or more agents selected from sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with other non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Pat. Nos. 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil medium for example peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxy-ethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbit
  • the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
  • preservatives for example ethyl, or n-propyl, p-hydroxybenzoate
  • coloring agents for example ethyl, or n-propyl, p-hydroxybenzoate
  • coloring agents for example ethyl, or n-propyl, p-hydroxybenzoate
  • flavoring agents for example ethyl, or n-propyl, p-hydroxybenzoate
  • sweetening agents such as sucrose or saccharin.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • a dispersing or wetting agent exemplified by those already mentioned above.
  • Additional excipients for example sweetening, flavoring and coloring agents, may also be present.
  • the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavoring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
  • sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
  • This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • compositions of the present invention may also be administered in the form of suppositories for rectal administration of the drug.
  • suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and polyethylene glycols.
  • creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of the present invention are employed.
  • topical application is also meant to include the use of mouth washes and gargles.
  • compositions and method of the present invention may further comprise other therapeutically active compounds as noted herein which are usually applied in the treatment of the above mentioned pathological conditions.
  • the present invention provides methods of treating or preventing a CCR4-mediated condition or disease by administering to a subject having such a condition or disease, a therapeutically effective amount of any compound of formula I above (e.g., without provisos) or a compound of formula II.
  • Preferred compounds for use in the present methods are those compounds provided above as preferred embodiments, as well as compounds specifically exemplified in the Examples below, and provided with specific structures herein.
  • the “subject” is defined herein to include animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like. In preferred embodiments, the subject is a human.
  • CCR4-mediated condition or disease refers to a condition or disease characterized by inappropriate, e.g., less than or greater than normal, CCR4 functional activity. Inappropriate CCR4 functional activity might arise as the result of CCR4 expression in cells which normally do not express CCR4, increased CCR4 expression (leading to, e.g., inflammatory and immunoregulatory disorders and diseases) or decreased CCR4 expression.
  • Inappropriate CCR4 functional activity might also arise as the result of TARC and/or MDC secretion by cells which normally do not secrete TARC and/or MDC, increased TARC and/or MDC expression (leading to, e.g., inflammatory and immunoregulatory disorders and diseases) or decreased TARC and/or MDC expression.
  • a CCR4-mediated condition or disease may be completely or partially mediated by inappropriate CCR4 functional activity.
  • a CCR4-mediated condition or disease is one in which modulation of CCR4 results in some effect on the underlying condition or disease (e.g., a CCR4 antagonist results in some improvement in patient well-being in at least some patients).
  • terapéuticaally effective amount means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
  • diseases and conditions associated with inflammation, infection and cancer can be treated or prevented with the present compounds and compositions.
  • diseases or conditions including chronic diseases, of humans or other species can be treated with inhibitors of CCR4 function.
  • diseases or conditions include: (1) allergic diseases such as systemic anaphylaxis or hypersensitivity responses, drug allergies, insect sting allergies and food allergies, (2) inflammatory bowel diseases, such as Crohn's disease, ulcerative colitis, ileitis and enteritis, (3) vaginitis, (4) psoriasis and inflammatory dermatoses such as dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria and pruritus, (5) vasculitis, (6) spondyloarthropathies, (7) scleroderma, (8) asthma and respiratory allergic diseases such as allergic asthma, allergic rhinitis, hypersensitivity lung diseases and the like, (9) autoimmune diseases, such as arthritis (including r
  • diseases or conditions can be treated with agonists of CCR4 function.
  • diseases to be treated with CCR4 agonists include cancers, diseases in which angiogenesis or neovascularization play a role (neoplastic diseases, retinopathy and macular degeneration), infectious diseases (viral infections, e.g., HIV infection, and bacterial infections) and immunosuppressive diseases such as organ transplant conditions and skin transplant conditions.
  • organ transplant conditions is meant to include bone marrow transplant conditions and solid organ (e.g., kidney, liver, lung, heart, pancreas or combination thereof) transplant conditions.
  • the present methods are directed to the treatment of diseases or conditions selected from allergic diseases, psoriasis, atopic dermatitis and asthma.
  • the compounds of the present invention may be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV, intracisternal injection or infusion, subcutaneous injection, or implant), inhalation, nasal, vaginal, rectal, sublingual, or topical routes of administration and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration.
  • the present invention also contemplates administration of the compounds of the present invention in a depot formulation.
  • an appropriate dosage level will generally be about 0.001 to 100 mg per kg patient body weight per day which can be administered in single or multiple doses.
  • the dosage level will be about 0.01 to about 25 mg/kg per day; more preferably about 0.05 to about 10 mg/kg per day.
  • a suitable dosage level may be about 0.01 to 25 mg/kg per day, about 0.05 to 10 mg/kg per day, or about 0.1 to 5 mg/kg per day. Within this range the dosage may be 0.005 to 0.05, 0.05 to 0.5 or 0.5 to 5.0 mg/kg per day.
  • compositions are preferably provided in the form of tablets containing 1.0 to 1000 milligrams of the active ingredient, particularly 1.0, 5.0, 10.0, 15.0. 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • the compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
  • the compounds of the present invention can be combined with other compounds having related utilities to prevent and treat inflammatory conditions and diseases, including allergic diseases, psoriasis, atopic dermatitis and asthma, and those pathologies noted above.
  • the present compounds may be used in conjunction with an antiinflammatory or analgesic agent such as an opiate agonist, a lipoxygenase inhibitor, such as an inhibitor of 5-lipoxygenase, a cyclooxygenase inhibitor, such as a cyclooxygenase-2 inhibitor, an interleukin inhibitor, such as an interleukin-1 inhibitor, an NMDA antagonist, an inhibitor of nitric oxide or an inhibitor of the synthesis of nitric oxide, a non-steroidal antiinflammatory agent, or a cytokine-suppressing antiinflammatory agent, for example with a compound such as acetaminophen, aspirin, codeine, fentanyl, ibuprofen, indomethacin, ketorolac, morphine, naproxen, phenacetin, piroxicam, a steroidal analgesic, sufentanyl, sunlindac, tenid
  • an antiinflammatory or analgesic agent such as an
  • the instant compounds may be administered with an analgesic listed above; a potentiator such as caffeine, an H2-antagonist (e.g., ranitidine), simethicone, aluminum or magnesium hydroxide; a decongestant such as phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxy-ephedrine; an antiitussive such as codeine, hydrocodone, caramiphen, carbetapentane, or dextromethorphan; a diuretic; and a sedating or non-sedating antihistamine.
  • a potentiator such as caffeine, an H2-antagonist (e.g., ranitidine), simethicone, aluminum or magnesium hydroxide
  • a decongestant such as phenylephrine, phenylpropan
  • compounds and compositions of the present invention may be used in combination with other drugs that are used in the treatment, prevention, suppression or amelioration of the diseases or conditions for which compounds of the present invention are useful.
  • Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of the present invention.
  • a pharmaceutical composition containing such other drugs in addition to the compound of the present invention is preferred.
  • the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients or therapeutic agents, in addition to a compound of the present invention.
  • Examples of other therapeutic agents that may be combined with a compound of the present invention, either administered separately or in the same pharmaceutical compositions include, but are not limited to: (a) VLA-4 antagonists, (b) corticosteroids, such as beclomethasone, methylprednisolone, betamethasone, prednisone, prenisolone, dexamethasone, fluticasone, hydrocortisone, budesonide, triamcinolone, salmeterol, salmeterol, salbutamol, formeterol; (c) immunosuppressants such as cyclosporine (cyclosporine A, Sandimmune®, Neoral®), tacrolimus (FK-506, Prograf®), rapamycin (sirolimus, Rapamune®) and other FK-506 type immunosuppressants, and mycophenolate, e.g., mycophenolate mofetil (CellCept®); (d) antihistamines (H1-histamine antagonist
  • the weight ratio of the compound of the present invention to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used. Thus, for example, when a compound of the present invention is combined with an NSAID the weight ratio of the compound of the present invention to the NSAID will generally range from about 1000:1 to about 1:1000, preferably about 200:1 to about 1:200. Combinations of a compound of the present invention and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.
  • the present methods are directed to the treatment of allergic diseases, wherein the compound of the invention is administered either alone or in combination with a second therapeutic agent, wherein said second therapeutic agent is an antihistamine.
  • the practitioner can administer a combination of the therapeutic agents, or administration can be sequential.
  • the present methods are directed to the treatment of psoriasis wherein the compound of the invention is used alone or in combination with a second therapeutic agent selected from a corticosteroid, a lubricant, a keratolytic agent, a vitamin D 3 derivative, PUVA and anthralin.
  • a second therapeutic agent selected from a corticosteroid, a lubricant, a keratolytic agent, a vitamin D 3 derivative, PUVA and anthralin.
  • the present methods are directed to the treatment of atopic dermatitis using a compound of the invention either alone or in combination with a second therapeutic agent selected from a lubricant and a corticosteroid.
  • the present methods are directed to the treatment of asthma using a compound of the invention either alone or in combination with a second therapeutic agent selected from a ⁇ 2-agonist and a corticosteroid.
  • the present invention includes methods to evaluate putative specific agonists or antagonists of CCR4 function. Accordingly, the present invention is directed to the use of these compounds in the preparation and execution of screening assays for compounds which modulate the function of the CCR4 chemokine receptor.
  • the compounds of this invention are useful for isolating receptor mutants, which are excellent screening tools for potent compounds.
  • the compounds of this invention are useful in establishing or determining the binding site of other compounds to the CCR4 chemokine receptor, e.g., by competitive inhibition.
  • the compounds of the instant invention are also useful for the evaluation of putative specific modulators of the CCR4 chemokine receptor, relative to other chemokine receptors including CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR5, CCR6, CCR8, CCR10, CXCR3 and CXCR4.
  • CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR5, CCR6, CCR8, CCR10, CXCR3 and CXCR4 One of skill in the art will appreciate that thorough evaluation of specific agonists and antagonists of the above chemokine receptors has been hampered by the lack of availability of non-peptidyl (metabolically resistant) compounds with high binding affinity for these receptors.
  • the compounds provided herein are particularly useful in this context.
  • Combinatorial libraries of putative CCR4 agonists or antagonists can be screened for pharmacological activity in in vitro or in vivo assays.
  • new chemical entities with useful properties are generated by identifying a chemical compound (called a “lead compound”) with some desirable property or activity, e.g., CCR4 chemokine receptor modulation activity, creating variants of the lead compound, and evaluating the properties and activities of those variant compounds.
  • CCR4 chemokine receptor modulation activity e.g., CCR4 chemokine receptor modulation activity
  • the current trend is to shorten the time scale for all aspects of drug discovery. Because of the ability to test large numbers of compounds quickly and efficiently, high throughput screening (HTS) methods are replacing conventional lead compound identification methods.
  • HTS high throughput screening
  • high throughput screening methods involve providing a library containing a large number of potential therapeutic compounds (candidate compounds). Such “combinatorial chemical libraries” are then screened in one or more assays to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional “lead compounds” or can themselves be used as potential or actual therapeutics.
  • a combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical “building blocks”, such as reagents.
  • a linear combinatorial chemical library such as a polypeptide (e.g., mutein) library, is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks (Gallop et. al. (1994) J. Med. Chem. 37(9):1233-1251).
  • combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Pat. No. 5,010,175, Furka (1991) Int. J. Pept. Prot. Res. 37:487-493, Houghton et. al. (1991) Nature 354: 84-88), peptoid libraries (PCT Publication No WO 91/19735), encoded peptide libraries (PCT Publication WO 93/20242), random bio-oligomer libraries (PCT Publication WO 92/00091), benzodiazepine libraries (U.S. Pat. No.
  • a number of well known robotic systems have also been developed for solution phase chemistries. These systems includes automated workstations like the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate II, Zymark Corporation, Hopkinton Mass.; Orca, Hewlett-Packard, Palo Alto Calif.), which mimic the manual synthetic operations performed by a chemist. Any of the above devices are suitable for use with the present invention. The nature and implementation of modifications to these devices (if any) so that they can operate as discussed herein will be apparent to persons skilled in the relevant art.
  • High throughput assays for the presence, absence, quantification, or other properties of particular compounds may be used to test a combinatorial library that contains a large number of potential therapeutic compounds (potential modulator compounds).
  • the assays are typically designed to screen large chemical libraries by automating the assay steps and providing compounds from any convenient source to the assays, which are typically run in parallel (e.g., in microtiter formats on microtiter plates in robotic assays).
  • Preferred assays detect enhancement or inhibition of CCR4 receptor function.
  • High throughput screening systems are commercially available (see e.g., Zymark Corp., Hopkinton Mass.; Air Technical Industries, Mentor Ohio; Beckman Instruments, Inc., Fullerton Calif.; Precision Systems, Inc., Natick Mass.; etc.). These systems typically automate entire procedures, including all sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detector(s) appropriate for the assay.
  • These configurable systems provide high throughput and rapid start-up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for various high throughput systems.
  • Zymark Corp. provides technical bulletins describing screening systems for detecting the modulation of gene transcription, ligand binding, and the like.
  • a variety of assays can be used to evaluate the compounds provided herein, including CCR4 binding assays, CCR4 signalling assays, chemotaxis assays, and other assays of cellular response.
  • a CCR4 protein (whether isolated or recombinant) which has at least one property, activity or functional charateristic of a mammalian CCR4 protein.
  • the property can be a binding property (to, for example, a ligand or inhibitor), a signalling activity (e.g., activation of a mammalian G protein, induction of rapid and transient increase in the concentration of cytosolic free calcium [Ca ++ ] i ), cellular response function (e.g., stimulation of chemotaxis or inflammatory mediator release by leukocytes), and the like.
  • a composition containing a CCR4 protein or variant thereof is maintained under conditions suitable for binding.
  • the CCR4 receptor is contacted with a putative agent (or a second composition containing at least one putative agent) to be tested, and binding is detected or measured.
  • the assay is a cell-based assay and cells are used which are stably or transiently transfected with a vector or expression cassette having a nucleic acid sequence which encodes the CCR4 receptor.
  • the cells are maintained under conditions appropriate for expression of the receptor and are contacted with a putative agent under conditions appropriate for binding to occur. Binding can be detected using standard techniques. For example, the extent of binding can be determined relative to a suitable control (for example, relative to background in the absence of a putative agent, or relative to a known ligand).
  • a cellular fraction, such as a membrane fraction, containing the receptor can be used in lieu of whole cells.
  • Detection of binding or complex formation can be detected directly or indirectly.
  • the putative agent can be labeled with a suitable label (e.g., fluorescent label, chemiluminescent label, isotope label, enzyme label, and the like) and binding can be determined by detection of the label.
  • a suitable label e.g., fluorescent label, chemiluminescent label, isotope label, enzyme label, and the like
  • binding can be determined by detection of the label.
  • Specific and/or competitive binding can be assessed by competition or displacement studies, using unlabeled agent or a ligand (e.g., TARC or MDC) as a competitor.
  • binding inhibition assays can be used to evaluate the present compounds.
  • the compounds are evaluated as inhibitors of ligand binding using, for example, TARC or MDC.
  • the CCR4 receptor is contacted with a ligand such as TARC or MDC and a measure of ligand binding is made.
  • the receptor is then contacted with a test agent in the presence of a ligand (e.g., TARC or MDC) and a second measurement of binding is made.
  • a reduction in the extent of ligand binding is indicative of inhibition of binding by the test agent.
  • the binding inhibition assays can be carried out using whole cells which express CCR4, or a membrane fraction from cells which express CCR4.
  • G protein activity such as hydrolysis of GTP to GDP
  • later signalling events triggered by receptor binding can be assayed by known methods (see, for example, PCT/US97/15915; Neote, et al., Cell, 72:415-425 (1993); Van Riper, et al., J. Exp. Med., 177:851-856 (1993) and Dahinden, et al, J. Exp. Med., 179:751-756 (1994)).
  • Chemotaxis assays can also be used to assess receptor function and evaluate the compounds provided herein. These assays are based on the functional migration of cells in vitro or in vivo induced by an agent, and can be used to assess the binding and/or effect on chemotaxis of ligands, inhibitors, or agonists. Suitable assays are described in PCT/US97/15915; Springer, et al., WO 94/20142; Berman et al., Immunol. Invest., 17:625-677 (1988); and Kavanaugh et al., J. Immunol., 146:4149-4156 (1991)).
  • the compounds provided herein can also be evaluated using models of inflammation to assess the ability of the compound to exert an effect in vivo. Suitable models are described as follows: a sheep model for asthma (see, Weg, et al., J. Exp. Med., 177:561 (1993)); and a rat delayed-type hypersensitivity model (see Rand, et al., Am. J. Pathol., 148:855-864 (1996)).
  • EAE experimental autoimmune encephalomyelitis
  • leukocyte infiltration assays can also be used to evaluate a compound (see, Van Damme, et al., J. Exp. Med. 176:59-65 (1992); Zachariae, et al., J. Exp. Med. 171:2177-2182 (1990); and Jose, et al., J. Exp. Med. 179:881-887 (1994)).
  • Reagents and solvents used below can be obtained from commercial sources such as Aldrich Chemical Co. (Milwaukee, Wis., USA).
  • 1 H-NMR spectra were recorded on a Varian Gemini 400 MHz NMR spectrometer. Significant peaks are tabulated in the order: number of protons, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br s, broad singlet) and coupling constant(s) in Hertz (Hz).
  • Electron Ionization (El) mass spectra were recorded on a Hewlett Packard 5989A mass spectrometer.
  • Mass spectrometry results are reported as the ratio of mass over charge, followed by the relative abundance of each ion (in parentheses). In tables, a single m/e value is reported for the M+H (or, as noted, M ⁇ H) ion containing the most common atomic isotopes. Isotope patterns correspond to the expected formula in all cases.
  • Electrospray ionization (ESI) mass spectrometry analysis was conducted on a Hewlett Packard 1100 MSD electrospray mass spectrometer using the HP1 100 HPLC for sample delivery.
  • the analyte was dissolved in methanol at 0.1 mg/mL and 1 microliter was infused with the delivery solvent into the mass spectrometer, which scanned from 100 to 1500 daltons. All compounds could be analyzed in the positive ESI mode, using 1:1 acetonitrile/water with 1% acetic acid as the delivery solvent. The compounds provided below could also be analyzed in the negative ESI mode, using 2 mM NH 4 OAc in acetonitrile/water as delivery solvent.
  • the desired thiazole products were precipitated from reaction solution. The isolation was then carried out by filtration through a Bückner funnel and washed the solid with acetone. The final products were isolated as the salt forms.
  • Compound 16 was prepared from N-naphthylthiourea (606 mg, 3.0 mmol) and 1-bromo-2,3-butanedione (4.0 mmol) according to general procedure 2. This material was carried to the next step without further purification.
  • Compound 18 was prepared from 4-iso-butylamino-2′-ethyl-2-naphthylamino thiazole and iso-butylaldehyde according to the general procedure of reductive amination outlined above. Purification of the crude product by HPLC afforded the desired product as white solid (61 mg, 50% yield).
  • This compound was prepared from 1-benzyl-3-bromo-4-piperidone (which is synthesized from 1-benzyl-4-piperidone by regioselective bromination) and N-naphthylthiourea following a general procedure. Purification of the crude product by HPLC gave (20) as white solid (178 mg, 48% yield).
  • This example illustrates a CCR4 binding assay that can be used for evaluating the compounds of the present invention.
  • 125 I-labelled TARC and MDC are available from commercial sources (e.g., Amersham-Pharmacia or Perkin Elmer Life Sciences). All buffers and materials are available from commercial sources (e.g., Gibco BRL, Sigma).
  • the 125 I-TARC or 125 I-MDC is diluted to a concentration of approximately 200 pM in a buffered saline solution (e.g., RPMI supplemented with 0.5% bovine serum albumin), and added to an equal volume of a suspension of cells (e.g., CEM cells at 5 ⁇ 10 6 cells/mL). The resulting mixture is incubated for a period of time (e.g., 2 hours).
  • a buffered saline solution e.g., RPMI supplemented with 0.5% bovine serum albumin
  • the unbound 125 I-TARC or 125 I-MDC is separated from the cells by filtration, e.g., by passage through GF/B filter plate (Packard Biosciences) pre-treated with 0.3% polyethyleneimine (Sigma), using a Packard Filtermate 96 (Packard Biosciences).
  • the amount of 125 I-TARC or 125 I-MDC retained with the cells on the filterplate is measured by adding a small amount of scintillation fluid (e.g., 50 ⁇ L of Microscint-20, obtained from Packard Biosciences), and reading scintillation on appropriate detection equipment, e.g., a Packard TopCount 383 (Packard Biosciences).
  • Non-specific binding of 125 I-TARC or 125 I-MDC can be estimated by measuring the amount of 125 I-TARC or 125 I-MDC retained with the cells on the filterplate when the assay is performed in the presence of a large excess of unlabelled TARC or MDC.
  • Inhibition of 125 I-TARC or 125 I-MDC binding to CCR4 is defined as a decrease in the retention of 125 I-TARC or 125 I-MDC to the cells on the filterplate.
  • Source plates of chemical libraries were obtained from commercial vendors and contained individual compounds at 5 mg/mL in DMSO, or in some instances, at 1 mg/nL. From these, multiple compound plates containing 10 compounds in each well were made, and these were diluted in 20% DMSO to a concentration of 50 ⁇ g/mL (10 ⁇ g/mL for those beginning at 1 mg/mL). An aliquot of 20 ⁇ L of each mixture was put into the test plates, which were stored frozen until use.
  • a CCR4 expressing stable transfectant cell line was prepared using current standard molecular biological methods.
  • the CCR4 transfectants were cultured in IMDM-5% FBS, and harvested when the concentration was between 0.5-1.0 ⁇ 10 6 cells/ml.
  • the cells were centrifuged and resuspended in assay buffer (20 mM HEPES pH 7.1, 140 mM NaCl, 1 mM CaCl 2 , 5mM MgCl 2 , and with 0.2% bovine serum albumin) to a concentration of 5.6 ⁇ 10 6 cells/ml.
  • assay buffer (20 mM HEPES pH 7.1, 140 mM NaCl, 1 mM CaCl 2 , 5mM MgCl 2 , and with 0.2% bovine serum albumin
  • Control wells containing either diluent only (for total counts) or excess MDC or TARC (1 ⁇ g/ml, for non-specific binding) were used to calculate the percent of total inhibition for each set of compounds. Further tests on individual compounds were carried out in the same manner. IC 50 values are those concentrations required to reduce the binding of labeled MDC or TARC to the receptor by 50%.
  • the calcium mobilization experiments were performed by labeling the human T-cell line CEM with NDO-1 dye (45 min at room temperature), washing with PBS, and resuspending into flux buffer (HBSS with 1% fetal bovine serum). For each test, 1 ⁇ 10 6 cells were incubated at 37° C. in the cuvette of a PTI spectrometer, and the ratio of 410/490 nm emission plotted over time (typically 2-3 minutes), with compounds added at 5 seconds, followed by MDC, TARC or other chemokines.
  • Chemotaxis assays were performed using 5 ⁇ filter plates (Neuroprobe) with the chemoattractant (MDC, TARC, or SDF) placed in the lower chamber, and a cell suspension of 100,000 CEM cells in the upper chamber. The assays were incubated 1-2 hours at 37° C., and the number of cells in the lower chamber quantified by the CyQuant assay (Molecular Probes).
  • This example describes a procedure to evaluate the efficacy of CCR4 antagonists for treatment of septic shock.
  • LPS lipopolysaccharide
  • Three series of mouse groups comprising 15 mice per group, are treated with an intra-peritoneal injection of an L.D.(lethal dose)-90 of LPS (precise dose requires titration of the particular batch of lipopolysaccharide in the actual mouse colony in use to determine a re-producible dose of LPS that produces 90% mortality in mice).
  • One series of mice additionally receives phosphate buffered saline (PBS) and Tween 0.5% i.p. 30 minutes before LPS administration.
  • PBS phosphate buffered saline
  • a second series consists of groups of mice receiving different doses of the CCR4 antagonist(s) given either intra-peritoneally, intra-venously, sub-cutaneously, intramuscularly, orally, or via any other mode of administration 30 minutes before, or concurrently with, LPS administration.
  • a third series of mice, serving as positive control, consists of groups treated with either mouse IL-10 i.p., or anti-TNF antibodies i.p., 30 minutes before LPS administration.
  • mice are monitored for death for 72 hours following the LPS injection.
  • This example describes a procedure to evaluate the efficacy of CCR4 antagonists for treatment of asthma.
  • An animal model of asthma can be induced by sensitizing rodents to an experimental antigen (e.g. OVA) by standard immunization, and then subsequently introducing that same antigen into the rodents lung by aerosolization.
  • an experimental antigen e.g. OVA
  • Three series of rodent groups comprising 10 rodents per goup, are actively sensitized on Day 0 by a single intraperitoneal injection with 100 ug OVA in phosphate-buffered saline (PBS), along with an IgE-selective adjuvant e.g. aluminum hydroxide.
  • PBS phosphate-buffered saline
  • IgE-selective adjuvant e.g. aluminum hydroxide.
  • mice At 11 days after sensitization, at the peak of their IgE response, the animals are placed in a Plexiglas chamber and challenged with aerosolized OVA (1%) for 30 minutes using the ultrasonic nebulizer (De Vilbliss).
  • One series of mice additionally receives phosphate buffered saline (PBS)and Tween 0.5% i.p. at the initial sensitization, and at different dosing schedules thereafter, up until the aerosolized OVA challenge.
  • PBS phosphate buffered saline
  • a second series consists of groups of mice receiving different doses of the CCR4 antagonist(s) given either intra-peritoneally, intra-venously, sub-cutaneously, intra-muscularly, orally, or via any other mode of administration at the initial sensitization, and at different dosing schedules thereafter, up until the aerosolized OVA challenge.
  • a third series of mice, serving as positive control consists of groups treated with either mouse IL-10 i.p., anti-IL4 antibodies i.p., or anti-IL5 antibodies i.p. at the initial sensitization, and at different dosing schedules thereafter, up until the aerosolized OVA challenge.
  • This example describes a procedure to evaluate the efficacy of CCR4 antagonists for augmenting protective immunity against viruses, bacteria and parasites.
  • Th1 regulatory T cells Protective immunity to microbial pathogens is frequently mediated by Th1 regulatory T cells. Since CCR4 antagonists are likely inhibitors of Th2 regulatory cells, they may alter the cross regulation that normally exists between Th1 and Th2 cells, and potentiate Th1 cells, thereby augmenting protection against infectious disease.
  • CCR4 antagonists are likely inhibitors of Th2 regulatory cells, they may alter the cross regulation that normally exists between Th1 and Th2 cells, and potentiate Th1 cells, thereby augmenting protection against infectious disease.
  • Three series of mouse groups comprising 15 mice per group, are infected with the intracellular parasite Leishmania major ( L.major ) by injecting L.major promastigotes sub-cutaneously into their left hind footpads. Four weeks after infection, the animals are challenged with either Leishmania freeze-thawed antigen, or PBS as a negative control, in the contra-lateral footpad.
  • mice additionally receives phosphate buffered saline (PBS)and Tween 0.5% i.p. at the initial sensitization, and at different dosing schedules thereafter, up until the Leishmania antigen challenge.
  • a second series consists of groups of mice receiving different doses of the CCR4 antagonist(s) given either intra-peritoneally, intra-venously, sub-cutaneously, intra-muscularly, orally, or via any other mode of administration at the initial sensitization, and at different dosing schedules thereafter, up until the Leishmania antigen challenge.
  • a third series of mice, serving as positive control consists of groups treated with either mice IL-12, anti-IL4 antibodies i.p., or anti-IL5 antibodies i.p. at the initial sensitization, and at different dosing schedules thereafter, up until the Leishmania antigen challenge.
  • This example describes a procedure to evaluate the efficacy of CCR4 antagonists for treatment of rheumatoid arthritis.
  • An animal model of rheumatoid arthritis can be induced in rodents by injecting them with type II collagen in selected adjuvants.
  • Three series of rodent groups consisting 15 genetically-susceptible mice or rats per group are injected sub-cutaneously or intra-dermally with type II collagen emulsified in Complete Freund's Adjuvant at days 0 and 21.
  • One series of rodents additionally receives phosphate buffered saline (PBS) and Tween 0.5% i.p. at the initial sensitization, and at different dosing schedules thereafter.
  • PBS phosphate buffered saline
  • a second series consists of groups of rodents receiving different doses of the CCR4 antagonist(s) given either intra-peritoneally, intravenously, sub-cutaneously, intra-muscularly, orally, or via any other mode of administration at the initial sensitization, and at different dosing schedules thereafter.
  • a third series of rodents, serving as positive control consists of groups treated with either mouse IL-10 i.p., or anti-TNF antibodies i.p.at the initial sensitization, and at different dosing schedules thereafter.
  • This example describes a procedure to evaluate efficacy of CCR4 antagonists for treatment of Systemic Lupus Erythematosus (SLE).
  • SLE Systemic Lupus Erythematosus
  • mice spontaneously develop an SLE-like pathology commencing at 6 months of age that is characterized by proteinuria, serum autoantibodies, glomerulonephritis, and eventually death.
  • Three series of NZB/W mouse groups comprising 20 mice per group are tested for efficacy of CCR antagonist(s) as follows: One series of mice additionally receives phosphate buffered saline (PBS) and Tween 0.5% i.p. soon after weaning, and thereafter at varying dosing schedules.
  • PBS phosphate buffered saline
  • a second series consists of groups of mice receiving different doses of the CCR4 antagonist(s) given either intra-peritoneally, intra-venously, sub-cutaneously, intra-muscularly, orally, or via any other mode of administration soon after weaning, and thereafter at varying dosing schedules.
  • a third series of mice, serving as positive control, consists of groups treated with anti-IL10 antibodies given soon after weaning, and thereafter at varying dosing schedules.
  • This example describes a procedure to evaluate efficacy of CCR4 antagonists for treatment of malignancy.
  • SCID mice can be transplanted with primary human tumor cells.
  • Normal mouse strains can be transplanted with a variety of well-characterized mouse tumor lines, including a mouse thymoma EL4 which has been transfected with OVA to allow easy evaluation of tumor specific antigen responses following vaccination with OVA.
  • Three series of mouse groups from any of these tumor models are tested for CCR4 antagonist efficacy as follows: One series of mice additionally receives phosphate buffered saline (PBS) and Tween 0.5% i.p. soon after tumor transplant, and thereafter at varying dosing schedules.
  • PBS phosphate buffered saline
  • a second series consists of groups of mice receiving different doses of the CCR4 antagonist(s) given either intra-peritoneally, intra-venously, sub-cutaneously, intra-muscularly, orally, or via any other mode of administration soon after tumor transplant, and thereafter at varying dosing schedules.
  • a third series of mice, serving as positive control, consists of groups treated with either anti-IL4 antibodies, anti-IFNg antibodies, IL4, or TNF, given i.p. soon after tumor transplant, and thereafter at varying dosing schedules.
  • Efficacy is monitored via tumor growth versus regression.
  • cytolytic OVA-specific responses can be measured by stimulating draining lymph node cells with OVA in vitro, and measuring antigen-specific cytotoxicity at 72 hours.
  • This example describes procedures to evaluate the efficacy of CCR4 antagonists in psoriasis.
  • a rodent model of psoriasis can be obtained by intra-venously transferring a population of purified T cells (designated CD45Rbhi T cells) obtained from the spleens of BALB/c mice into immunodeficient recipient CB.17 scid/scid mice. Mice develop signs of redness, swelling, and skin lesions resembling those of human psoriasis in their ear, feet and tail by 8 weeks after transfer. Three series of mouse groups, comprising 10-15 CB.17 scid/scid mice per group, are injected with purified CD45Rbhi T cells. One series of mice additionally receives phosphate buffered saline (PBS) and Tween 0.5% i.p.
  • PBS phosphate buffered saline
  • a second series consists of groups of mice receiving different doses of the CCR4 antagonist(s) given either intra-peritoneally, intravenously, sub-cutaneously, intramuscularly, orally, or via any other mode of administration at the initial cell transfer, and at different dosing schedules thereafter.
  • a third series of mice, serving as positive control, consists of groups treated with antibodies to either IL-12, IL-4, IFNg, or TNF, or with cytokine IL-10 at the initial cell transfer, and at different dosing schedules thereafter. Animals are monitored for development of psoriatic-like lesions for 3 months after cell transfer.
  • This example describes a procedure to evaluate the efficacy of CCR4 antagonists in Inflammatory Bowel Disease (IBD).
  • IBD Inflammatory Bowel Disease
  • mice [0222] Several mouse models of IBD (including Crohn's Disease and Ulcerative Colitis) have been developed. Some of these are spontaneous models occurring in genetically engineered transgenic mice that have been depleted of certain cytokine genes (e.g. IL-10, or IL-2) by homologous recombination. Another mouse model of Inflammatory Bowel Disease is obtained by transferring highly purified populations of CD4+T lymphocytes bearing a particular surface marker phenotype (namely CD45 RB hi) into SCID mice. Three series of mouse groups from any one of these models can be used to evaluate CCR4 antagonist efficacy as follows. One group of mice additionally receives phosphate buffered saline (PBS) and Tween 0.5% i.p.
  • PBS phosphate buffered saline
  • a second series consists of groups of mice receiving different doses of the CCR4 antagonist(s) given either intra-peritoneally, intra-venously, sub-cutaneously, intramuscularly, orally, or via any other mode of administration soon after weaning in the case of the spontaneous models in transgenic mice, or at time of cell transfer into SCID mice and varying dosings thereafter for the cell transfer model.
  • a third series of mice serving as positive control, consists of groups treated with antibodies to either IFNg, or TNF, or with cytokine IL-10 soon after weaning in the case of the spontaneous models in transgenic mice, or at time of cell transfer into SCID mice and varying dosings thereafter for the cell transfer model.
  • mice are evaluated for 6-8 weeks for disease development, monitored initially via weight loss and/or prolapsed rectum, and eventually by histological evaluation of the animals colon and intestinal tract.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.

Description

    CROSS-REFERENCES TO RELATED APPLICATIONS
  • This application claims the benefit of Provisional Application Ser. No. 60/240,022, filed Oct. 11, 2000, and further claims the benefit of Provisional Application Ser. No. 60/293,781, filed May 23, 2001, the disclosures of each being incorporated herein by reference.[0001]
    • STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
  • Not applicable [0002]
    • BACKGROUND OF THE INVENTION
  • Chemokines are chemotactic cytokines that are released by a wide variety of cells to attract macrophages, T cells, eosinophils, basophils and neutrophils to sites of inflammation (reviewed in Schall, [0003] Cytokine, 3:165-183 (1991), Schall, et al, Curr. Opin. Immunol. 6:865-873 (1994) and Murphy, Rev. Immun., 12:593-633 (1994)). In addition to stimulating chemotaxis, other changes can be selectively induced by chemokines in responsive cells, including changes in cell shape, transient rises in the concentration of intracellular free calcium ions ([Ca2+]) i, granule exocytosis, integrin upregulation, formation of bioactive lipids (e.g., leukotrienes) and respiratory burst, associated with leukocyte activation. Thus, the chemokines are early triggers of the inflammatory response, causing inflammatory mediator release, chemotaxis and extravasation to sites of infection or inflammation.
  • There are four classes of chemokines, CXC (α), CC (β), C(γ), and CX[0004] 3C (δ), depending on whether the first two cysteines are separated by a single amino acid (C—X—C), are adjacent (C—C), have a missing cysteine pair (C), or are separated by three amino acids (CX3C). The α-chemokines, such as interleukin-8 (IL-8), melanoma growth stimulatory activity protein (MGSA), and stromal cell derived factor 1 (SDF-1) are chemotactic primarily for neutrophils and lymphocytes, whereas β-chemokines, such as RANTES, MIP-1α, MIP-1β, monocyte chemotactic protein-1 (MCP-1), MCP-2, MCP-3 and eotaxin are chemotactic for macrophages, T-cells, eosinophils and basophils (Deng, et al., Nature, 381:661-666 (1996)). The C chemokine lymphotactin shows specificity for lymphocytes (Kelner, et al., Science, 266:1395-1399 (1994)) while the CX3C chemokine fractalkine shows specificity for lymphocytes and monocytes (Bazan, et al., Nature, 385:640-644 (1997).
  • Chemokines bind to specific cell-surface receptors belonging to the family of G-protein-coupled seven-transmembrane-domain proteins (reviewed in Horuk, [0005] Trends Pharm. Sci. 15:159-165 (1994)) which are termed “chemokine receptors.” On binding their cognate ligands, chemokine receptors transduce an intracellular signal through the associated heterotrimeric G protein, resulting in a rapid increase in intracellular calcium concentration. There are at least twelve human chemokine receptors that bind or respond to β-chemokines with the following characteristic pattern: CCR1 (or “CKR-1” or “CC-CKR-1”) to MIP-1α, MIP-1β, MCP-3, RANTES (Ben-Barruch, et al., J. Biol. Chem., 270:22123-22128 (1995); Neote, et al., Cell, 72:415-425 (1993)); CCR2A and CCR2B (or “CKR-2A”/“CKR-2A” or “CC-CKR-2A”/“CC-CKR2A”) to MCP-1, MCP-3, MCP-4; CCR3 (or “CKR-3” or “CC-CKR-3”) to eotaxin, RANTES, MCP; (Ponath, et al., J. Exp. Med., 183:2437-2448 (1996)); CCR4 (also referred to as “CKR-4”,“CC-CKR-4” or “CMKBR4”), to TARC, MDC (Imai et al. (1998) J. Biol. Chem. 273:1764-1768); CCR5 (or “CKR-5” or “CC-CKR-5”) to MIP-1α, RANTES, MIP-1β (Sanson, et al., Biochemistry, 35:3362-3367 (1996)); CCR6 to MIP-3 alpha (Greaves, et al., J. Exp. Med., 186:837-844 (1997)); CCR7 to MIP-3 beta and 6Ckine (Campbell, et al., J. Cell. Biol., 141:1053-1059(1998)); CCR8 to I-309, HHV8 vMIP-I, HHV-8 vMIP-II, MCV vMCC-I (Dairaghi, et al., J. Biol. Chem., 274:21569-21574 (1999)); CCR9 to TECK (Zaballos, et al., J. Immunol., 162:5671-5675 (1999)), D6 MIP-1 beta, RANTES, and MCP-3 (Nibbs, et al., J. Biol. Chem., 272:32078-32083 (1997)), the Duffy blood-group antigen to IL-8, Groα, RANTES, MCP-1 (Chaudhun et al. (1994) J. Biol. Chem. 269:7835-7838, Murphy et al. (2000) Pharm. Rev. 52:145-176) and CCR10 to CTACK, CCL28 (Jarmin et al. (2000) J. Immunol. 164:3460-3464, Homey et al. (2000) J. Immunol. 164:3465-3470, Wang et al. (2000) J. Biol. Chem. 275:22313-22323).
  • Chemokine receptors, such as CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CX[0006] 3CR1 and XCR1 have been implicated as being important mediators of inflammatory and immunoregulatory disorders and diseases, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis.
  • The CCR4 chemokine receptor, first identified by Power et al. (Power et al. (1995) [0007] J. Biol. Chem. 270:19495-19500), is expressed primarily in peripheral blood T lymphocytes. CCR4 is involved in T lymphocyte homing to the skin and lungs (see, e.g., Campbell et al. (1999) Nature 400:776-780, Gonzalo et al. (1999) J. Immunol. 163:403-411, Lloyd et al. (2000) J. Exp. Med. 191:265-273, Kawasaki et al. (2001) J. Immunol. 166:2055-2062).
  • The identification of compounds that modulate the function of CCR4 represents an attractive approach to the development of therapeutic agents for the treatment of inflammatory conditions and diseases associated with CCR4 activation, such as psoriasis, asthma and allergic diseases. [0008]
    • SUMMARY OF THE INVENTION
  • The present invention is directed to compounds which are modulators of CCR4 chemokine receptor function and are useful in the prevention or treatment of inflammatory conditions and diseases such as allergic diseases, psoriasis, atopic dermatitis and asthma. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases in which CCR4 chemokine receptors are involved. [0009]
  • In one aspect, the present invention provides compounds having the general formula (I): [0010]
    Figure US20020173524A1-20021121-C00001
  • wherein W is selected from aryl, heteroaryl, (C[0011] 1-C8)alkyl, heteroalkyl, cycloalkyl and heterocycloalkyl; X is selected from N(R5), S, O, C(R3)═C(R4), N═C(R4), and optionally, when Z is N, X can be C(R6)(R7); Y is selected from a bond, N(R5), N(R5)-(C1-C8)alkylene, O, S and S(O)n, wherein the integer n is 1 or 2; and Z is selected from N and C(R8). R1 and R2 are independently selected from H, halogen, CN, CO2R′, CONR′R″, (C1-C8)alkyl, heteroalkyl, aryl, heteroaryl, N(R6)(R7), OR9 and optionally, R1 and R2 combine to form a 5- to 8-membered ring containing from 0 to 3 heteroatoms selected from N, O and S, wherein R′ and R″ are independently selected from H, (C1-C8)alkyl and aryl. When R′ and R″ are attached to nitrogen, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. R3, R4 and R8 are independently selected from H, halogen, CN, OH, (C1-C8)alkyl, heteroalkyl, aryl, heteroaryl, O(C1-C8)alkyl, N(R6)(R7) and OR9; R5 is selected from H, (C1-C8)alkyl, heteroalkyl, aryl and heteroaryl; R6 and R7 are independently selected from H, (C1-C8)alkyl, heteroalkyl, aryl and heteroaryl; and R9 is selected from (C1-C8)alkyl, heteroalkyl and haloalkyl; with the provisos that R1 is other than phenyl, when W is phenyl or unsubstituted naphthyl, X is S, Y is NH, and Z is N; and R2 is other than H when W is unsubstituted phenyl, X is S, Y is NH, Z is N and R1 is (C1-C8)alkyl.
  • Unless otherwise indicated, the compounds provided in the above formula are meant to include pharmaceutically acceptable salts and prodrugs thereof. [0012]
  • A number of embodiments are preferred within the above formula. Among the preferred, but separate, embodiments, are those wherein Z is N; wherein X is S; wherein Y is N(R[0013] 5); wherein Z is N, X is S and Y is N(R5); wherein W is aryl or heteroaryl; wherein W is aryl or heteroaryl and aryl is phenyl or naphthyl; wherein W is aryl or heteroaryl and heteroaryl is pyridyl or quinolyl; wherein R1 and R2 are independently H or (C1-C8)alkyl; wherein R1 and R2 combine to form a fused 6-membered aryl or heteroaryl ring; wherein W is aryl or heteroaryl, X is S, Y is N(R5), Z is N, and R1 and R2 are independently H or (C1-C8)alkyl; wherein W is aryl or heteroaryl, X is S, Y is N(R5), Z is N, and R1 and R2 combine to form a fused 6-membered aryl or heteroaryl ring.
  • In one group of preferred embodiments, the compound is represented by formula (Ia): [0014]
    Figure US20020173524A1-20021121-C00002
  • wherein W, Y, R[0015] 1 and R2 have the meanings provided above.
  • In another aspect, the present invention provides a composition comprising a pharmaceutically acceptable carrier and a compound of formula I as provided above, or a compound of formula I wherein R[0016] 1 is phenyl, when W is phenyl or unsubstituted naphthyl, X is S, Y is NH, and Z is N; and R2 is H when W is unsubstituted phenyl, X is S, Y is NH, Z is N and R1 is (C1-C8)alkyl.
  • In still another aspect, the present invention provides a method of treating a CCR4-mediated condition or disease, comprising administering to a subject in need of such treatment, a therapeutically effective amount of a composition as described herein. [0017]
  • In preferred, but separate, embodiments of this aspect of the invention the CCR4-mediated condition or disease is selected from an allergic disease, psoriasis, atopic dermatitis and asthma; the CCR4-mediated condition or disease is an allergic disease; the CCR4-mediated condition or disease is an allergic disease and the allergic disease is selected from systemic anaphylaxis, hypersensitivity responses, drug allergies, insect sting allergies and food allergies; the CCR4-mediated condition or disease is psoriasis; the CCR4-mediated condition or disease is atopic dermatitis; the CCR4-mediated condition or disease is asthma; the CCR4-mediated condition or disease is an allergic condition and the compound is used alone or in combination with at least one therapeutic agent wherein the therapeutic agent is an antihistamine; the CCR4-mediated condition or disease is psoriasis and the compound is used alone or in combination with at least one therapeutic agent selected from a corticosteroid, a lubricant, a keratolytic agent, a vitamin D[0018] 3 derivative, PUVA and anthralin; the CCR4-mediated condition or disease is atopic dermatitis and the compound is used alone or in combination with at least one therapeutic agent selected from a lubricant and a corticosteroid; the CCR4-mediated condition or disease is asthma and the compound is used alone or in combination with at least one therapeutic agent selected from a β2-agonist and a corticosteroid; the compound interferes with the interaction between CCR4 and a ligand; the subject is a human.
  • In yet another aspect, the present invention provides a a method of modulating CCR4 function in a cell, comprising contacting the cell with a therapeutically effective amount of a compound of formula I. [0019]
  • In still another aspect, the present invention provides a method for modulating CCR4 function, comprising contacting a CCR4 protein with a therapeutically effective amount of a compound of formula I. [0020]
  • In another aspect, the present invention provides compositions and methods using compounds having the general formula: [0021]
  • Ar1—X—Ar2   (II)
  • in which the symbols Ar[0022] 1 and Ar2 each independently represent a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a substituted or unsubstituted fused aryl-heterocyclic ring system. The letter X represents a linking group selected from —N(R)—, —C(O)S—, —CH═CHSO2— and —SO2N(R)— wherein R is H or a substituted or unsubstituted (C1-C8)alkyl group. In this formula, the linking group can be in either orientation relative to the Ar1 and Ar2 moieties. For example, the above general formula is meant to include both Ar1—SO2—NH—Ar2 and Ar1—NH—SO2—Ar2. These compounds are useful in compositions and methods for the treatment of CCR4-mediated conditions or diseases, particularly those recited above with reference to compounds of formula I.
    •  BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a graph showing the results of a CCR4/TARC competition assay using compound 1.1. [0023]
  • FIG. 2 is a graph showing the results of a CCR4/TARC competition assay using compound 1.2. [0024]
  • FIG. 3 is a graph showing the results of a CCR4/TARC competition assay using compound 1.3. [0025]
  • FIG. 4 illustrates the results achieved with compound 1.2 in CEM migration assays with CCR4 and TARC. [0026]
  • FIG. 5 illustrates the effect of compound 1.3 on CEM calcium response. [0027]
  • FIG. 6 illustrates the effect of compound 1.2 on CEM calcium response.[0028]
    • DESCRIPTION OF THE INVENTION
  • Abbreviations and Definitions [0029]
  • The term “alkyl,” by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (i.e. C[0030] 1-C10 means one to ten carbons). Examples of saturated hydrocarbon radicals include groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers. The term “alkyl,” unless otherwise noted, is also meant to include those derivatives of alkyl defined in more detail below as “heteroalkyl.” Alkyl groups which are limited to hydrocarbon groups are termed “homoalkyl”.
  • The term “alkylene” by itself or as part of another substituent means a divalent radical derived from an alkane, as exemplified by —CH[0031] 2CH2CH2CH2—, and further includes those groups described below as “heteroalkylene.” Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention. A “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.
  • The terms “alkoxy,” “alkylamino” and “alkylthio” (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively. [0032]
  • The term “heteroalkyl,” by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and from one to three heteroatoms selected from the group consisting of O, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N and S may be placed at any interior position of the heteroalkyl group. The heteroatom Si may be placed at any position of the heteroalkyl group, including the position at which the alkyl group is attached to the remainder of the molecule. Examples include —CH[0033] 2—CH2—O—CH3, —CH2—CH2—NH—CH3, —CH2—CH2—N(CH3)—CH3, —CH2—S—CH2—CH3, —CH2—CH2, —S(O)—CH3, —CH2—CH2—S(O)2—CH3, —CH═CH—O—CH3, —Si(CH3)3, —CH2—CH═N—OCH3, and —CH═CH—N(CH3)—CH3. Up to two heteroatoms may be consecutive, such as, for example, —CH2—NH—OCH3 and —CH2—O—Si(CH3)3. Similarly, the term “heteroalkylene” by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified by —CH2—CH2—S—CH2CH2— and —CH2—S—CH2—CH2—NH—CH2—. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied.
  • The terms “cycloalkyl” and “heterocycloalkyl”, by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl”, respectively. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-moorpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like. [0034]
  • The terms “halo” or “halogen,” by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as “haloalkyl,” are meant to include monohaloalkyl and polyhaloalkyl. For example, the term “halo(C[0035] 1-C4)alkyl” is mean to include trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
  • The term “aryl” means, unless otherwise stated, a polyunsaturated, typically aromatic, hydrocarbon substituent which can be a single ring or multiple rings (up to three rings) which are fused together or linked covalently. The term “heteroaryl” refers to aryl groups (or rings) that contain from zero to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quatemized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below. [0036]
  • For brevity, the term “aryl” when used in combination with other terms (e.g., aryloxy, arylthioxy, arylalkyl) includes both aryl and heteroaryl rings as defined above. Thus, the term “arylalkyl” is meant to include those radicals in which an aryl group is attached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl and the like) including those alkyl groups in which a carbon atom (e.g., a methylene group) has been replaced by, for example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naphthyloxy)propyl, and the like). [0037]
  • Each of the above terms (e.g., “alkyl,” “heteroalkyl,” “aryl” and “heteroaryl”) are meant to include both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below. [0038]
  • Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be a variety of groups selected from: —OR′, ═O, ═NR′, ═N—OR′, —NR′R″, —SR′, -halogen, —SiR′R″R′″, —OC(O)R′, —C(O)R′, —CO[0039] 2R′, —CONR′R″, —OC(O)NR′R″, —NR″C(O)R′, —NR′—C(O)NR″R′″, —NR″C(O)2R′, —NH—C(NH2)═NH, —NR′C(NH2)═NH, —NH—C(NH2)═NR′, —S(O)R′, —S(O)2R′, —S(O)2NR′R″, —CN and —NO2 in a number ranging from zero to (2 m′+1), where m′ is the total number of carbon atoms in such radical. R′, R″ and R′″ each independently refer to hydrogen, unsubstituted (C1-C8)alkyl and heteroalkyl, unsubstituted aryl, aryl substituted with 1-3 halogens, unsubstituted alkyl, alkoxy or thioalkoxy groups, or aryl-(C1-C4)alkyl groups. When R′ and R″ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. For example, —NR′R″ is meant to include 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term “alkyl” is meant to include groups such as haloalkyl (e.g., —CF3 and —CH2CF3) and acyl (e.g., —C(O)CH3, —C(O)CF3, —C(O)CH2OCH3, and the like).
  • Similarly, substituents for the aryl and heteroaryl groups are varied and are selected from: -halogen, —OR′, —OC(O)R′, —NR′R″, —SR′, —R′, —CN, —NO[0040] 2, —CO2R′, —CONR′R″, —C(O)R′, —OC(O)NR′R″, —NR″C(O)R′, —NR″C(O)2R′, , —NR′—C(O)NR″R′″, —NH—C(NH2)═NH, —NR′C(NH2)═NH, —NH—C(NH2)═NR′, —S(O)R′, —S(O)2R′, —S(O)2NR′R″, —N3, —CH(Ph)2, perfluoro(C1-C4)alkoxy, and perfluoro(C1-C4)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R′, R″ and R′″ are independently selected from hydrogen, (C1-C8)alkyl and heteroalkyl, unsubstituted aryl and heteroaryl, (unsubstituted aryl)-(C1-C4)alkyl, and (unsubstituted aryl)oxy-(C1-C4)alkyl.
  • Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula —T—C(O)—(CH[0041] 2)q—U—, wherein T and U are independently —NH—, —O—, —CH2— or a single bond, and q is an integer of from 0 to 2. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula —A—(CH2)r—B—, wherein A and B are independently —CH2—, —O—, —NH—, —S—, —S(O)—, —S(O)2—, —S(O)2NR′— or a single bond, and r is an integer of from 1 to 3. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula —(CH2)s—X—(CH2)t—, where s and t are independently integers of from 0 to 3, and X is —O—, —NR′—, —S—, —S(O)—, —S(O)2—, or —S(O)2NR′—. The substituent R′ in —NR′— and —S(O)2NR′— is selected from hydrogen or unsubstituted (C1-C6) alkyl.
  • As used herein, the term “heteroatom” is meant to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si). [0042]
  • The term “pharmaceutically acceptable salts” is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge, S. M., et al, “Pharmaceutical Salts”, [0043] Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
  • The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention. [0044]
  • In addition to salt forms, the present invention provides compounds which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. [0045]
  • Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention. [0046]
  • Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are all intended to be encompassed within the scope of the present invention. [0047]
  • The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ([0048] 3H), iodine-125 (125I) or carbon-14 (14C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.
  • General [0049]
  • Chemokine receptors are attractive targets for the development of antiinflammatory agents. Small molecule antagonists of chemokine receptors, e.g., CC chemokine receptors, however, are not widely known. U.S. Pat. No. 6,207,665 to Hesselgesser et al. describes piperazine derivatives as CCR1 antagonists and is hereby incorporated by reference. [0050]
  • The present invention is directed to compounds, compositions and methods useful in the modulation of chemokine receptor function, particularly CCR4 function. Accordingly, the compounds of the present invention are compounds which inhibit at least one function or characteristic of a mammalian CCR4 protein, for example, a human CCR4 protein. [0051]
  • The full-length human CCR4 protein (GenBank Accession No. X85740; SWISS-PROT Accession No. P51679) has been described, see, e.g, Imai et al. (1998) [0052] J. Biol. Chem. 273:1764-1768, and has the sequence shown in SEQ ID NO:1.
  • The ability of a compound to inhibit the function of CCR4, can be demonstrated in a binding assay (e.g., ligand binding or agonist binding), a signalling assay (e.g., activation of a mammalian G protein, induction of rapid and transient increase in the concentration of cytosolic free calcium), and/or cellular response assay (e.g., stimulation of chemotaxis, exocytosis or inflammatory mediator release by leukocytes). [0053]
  • In view of the above, the present invention is directed to compounds, compositions and methods useful in the modulation of chemokine receptor activity, particularly CCR4. Accordingly, the compounds of the present invention are those which inhibit at least one function or characteristic of a mammalian CCR4 protein, for example, a human CCR4 protein. The ability of a compound to inhibit such a function can be demonstrated in a binding assay (e.g., ligand binding or promotor binding), a signalling assay (e.g., activation of a mammalian G protein, induction of rapid and transient increase in the concentration of cytosolic free calcium), and/or cellular response function (e.g., stimulation of chemotaxis, exocytosis or inflammatory mediator release by leukocytes). [0054]
  • Compounds that Modulate CCR4 Activity [0055]
  • CCR4 Antagonists [0056]
  • The present invention provides compounds having antiinflammatory or anti-immunoregulatory activity. The compounds of the invention are thought to interfere with inappropriate T-cell trafficking by specifically modulating or inhibiting a chemokine receptor function. Chemokine receptors are integral membrane proteins which interact with an extracellular ligand, or chemokine, and mediate a cellular response to the chemokine, e.g., chemotaxis, increased intracellular calcium ion concentration. Therefore, inhibition of a chemokine receptor function, e.g., interference with a chemokine receptor-ligand interaction, will inhibit a chemokine receptor-mediated response and treat or prevent a chemokine receptor-mediated condition or disease. [0057]
  • Without intending to be bound by theory, it is believed that the compounds provided herein interfere with the interaction between a chemokine receptor and one or more cognate ligands. In particular, it is believed that the compounds interfere with the interaction between CCR4 and a CCR4 ligand, e.g., TARC, MDC, etc. Compounds contemplated by the invention include, but are not limited to, the exemplary compounds provided herein. [0058]
  • The compounds provided herein have the general formula (I): [0059]
    Figure US20020173524A1-20021121-C00003
  • wherein W is selected from aryl, heteroaryl, (C[0060] 1-C8)alkyl, heteroalkyl, cycloalkyl and heterocycloalkyl; X is selected from N(R5), S, O, C(R3)═C(R4), N═C(R4), and optionally, when Z is N, X can be C(R6)(R7); Y is selected from a bond, N(R5), N(R5)-(C1-C8)alkylene, O, S and S(O)n, wherein the integer n is 1 or 2; and Z is selected from N and C(R8). R1 and R2 are independently selected from H, halogen, CN, CO2R′, CONR′R″, (C1-C8)alkyl, heteroalkyl, aryl, heteroaryl, N(R6)(R7), OR9 and optionally, R1 and R2 combine to form a 5- to 8-membered ring containing from 0 to 3 heteroatoms selected from N, O and S, wherein R′ and R″ are independently selected from H, (C1-C8)alkyl and aryl. When R′ and R″ are attached to nitrogen, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. R3, R4 and R8 are independently selected from H, halogen, CN, OH, (C1-C8)alkyl, heteroalkyl, aryl, heteroaryl, O(C1-C8)alkyl, N(R6)(R7) and OR9; R5 is selected from H, (C1-C8)alkyl, heteroalkyl, aryl and heteroaryl; R6 and R7 are independently selected from H, (C1-C8)alkyl, heteroalkyl, aryl and heteroaryl; and R9 is selected from (C1-C8)alkyl, heteroalkyl and haloalkyl; with the provisos that R1 is other than phenyl, when W is phenyl or unsubstituted naphthyl, X is S, Y is NH, and Z is N; and R2 is other than H when W is unsubstituted phenyl, X is S, Y is NH, Z is N and R1 is (C1-C8)alkyl.
  • Embodiments represented by formula I can be appreciated by replacing the ring system containing X and Z with an appropriate scaffold, wherein the attachment points represent the attachment of Y, R[0061] 1 and R2 groups:
    Figure US20020173524A1-20021121-C00004
  • For example, the ring system or “scaffold” is meant to include the following (including substituted versions thereof) wherein the “A” ring is selected from the following embodiments: [0062]
    Figure US20020173524A1-20021121-C00005
  • In one group of preferred embodiments Z is N. In another group, X is S. In still another group of preferred embodiments, Y is N(R[0063] 5). Particularly preferred are those embodiments that combine each of these preferred groups. Accordingly, in one group of particularly preferred embodiments X is S, Y is N(R5) and Z is N.
  • In another group of preferred embodiments, W is selected from aryl and heteroaryl. Particularly preferred are those embodiments in which aryl is phenyl or naphthyl. Other particularly preferred embodiments are those in which heteroaryl is pyridyl or quinolyl. In separate, but preferred embodiments, R[0064] 1 and R2 are independently H or (C1-C8)alkyl. In still other separate, but preferred embodiments, R1 and R2 combine to form a fused 6-membered aryl or heteroaryl ring. In each of the above groups of preferred embodiments, R5 is most preferably H.
  • In another group of preferred embodiments, the compounds of the invention have the formula(I), wherein W is selected from substituted naphthyl, pyridyl quinolyl, (C[0065] 1-C8)alkyl, heteroalkyl, cycloalkyl and heterocycloalkyl; X is selected from N(R5), S, O, C(R3)═C(R4), N═C(R4), and optionally, when Z is N, X can be C(R6)(R7); Y is selected from a bond, N(R5), N(R5)-(C1-C8)alkylene, 0, S and S(O)n, wherein the integer n is 1 or 2; and Z is selected from N and C(R8). R1 and R2 are independently selected from H, halogen, CN, CO2R′, CONR′R″, (C1-C8)alkyl, heteroalkyl, aryl, heteroaryl, N(R6)(R7), OR9 and optionally, R1 and R2 combine to form a 5- to 8-membered ring containing from 0 to 3 heteroatoms selected from N, O and S, wherein R′ and R″ are independently selected from H, (C1-C8)alkyl and aryl. When R′ and R″ are attached to nitrogen, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. R3, R4 and R8 are independently selected from H, halogen, CN, OH, (C1-C8)alkyl, heteroalkyl, aryl, heteroaryl, O(C1-C8)alkyl, N(R6)(R7) and OR9; R5 is selected from H, (C1-C8)alkyl, heteroalkyl, aryl and heteroaryl; R6 and R7 are independently selected from H, (C1-C8)alkyl, heteroalkyl, aryl and heteroaryl; and R9 is selected from (C1-C8)alkyl, heteroalkyl and haloalkyl.
  • A number of embodiments are particularly preferred within this group and are separately provided as those wherein Z is N; wherein X is S; wherein Y is N(R[0066] 5); wherein Z is N, X is S and Y is N(R5); wherein W is substituted naphthyl; wherein W is pyridyl or quinolyl; wherein R1 is other than phenyl; wherein R1 and R2 are independently H or (C1-C8)alkyl; wherein R1 and R2 combine to form a fused 6-membered aryl or heteroaryl ring; wherein W is substituted naphthyl, X is S, Y is N(R5), Z is N, and R1 and R2 are independently H or (C1-C8)alkyl; wherein W is substituted naphthyl, X is S, Y is N(R5), Z is N, and R1 and R2 combine to form a fused 6-membered aryl or heteroaryl ring; wherein W is pyridyl or quinolyl, X is S, Y is N(R5), Z is N, and R1 and R2 are independently H or (C1-C8)alkyl; and wherein W is pyridyl or quinolyl, X is S, Y is N(R5), Z is N, and R1 and R2 combine to form a fused 6-membered aryl or heteroaryl ring.
  • In a particularly preferred group of embodiments, the A ring is a thiazole ring (see formula Ia). [0067]
    Figure US20020173524A1-20021121-C00006
  • In formula Ia, W, Y, R[0068] 1 and R2 have the meanings (and preferred groupings) provided above. Exemplary structures within this preferred group of embodiments are shown below.
    Figure US20020173524A1-20021121-C00007
  • The compounds provided above are contemplated for use in compositions and methods for the treatment of CCR4-mediated conditions and diseases as described in more detail below. However, the present invention further includes aspects directed to pharmaceutical compositions and methods using compounds that are known, particularly those that are commercially available. Exemplary commercially available compounds include: 4-(1,1 -dimethylethyl)-N-phenyl-2-thiazolamine, 4-methyl-N-phenyl-2-thiazolamine, 4-(1-methylethyl)-N-phenyl-2-thiazolamine, 4-dodecyl-N-phenyl-2-thiazolamine, 2-anilino-4-isobutyl-thiazole, and 2-anilino-4-methyl-thiazole picrate. [0069]
  • Still other commercially available compounds that are useful in the composition and method aspects of this invention include: [0070]
    Figure US20020173524A1-20021121-C00008
  • Synthesis of CCR4 Antagonists [0071]
  • Synthesis routes to the compounds provided above are described in the Examples. One of skill in the art will appreciate that the substituents (e.g., R′, R″, R′″, etc.) can be altered before, during or after preparation of the heterocyclic scaffolding and that suitable adjustments in the exemplary conditions (e.g., temperatures, solvents, etc.) can be made. Additionally, one of skill in the art will recognize that protecting groups may be necessary for the preparation of certain compounds and will be aware of those conditions compatible with a selected protecting group. [0072]
  • Compositions that Modulate CCR4 Activity [0073]
  • In another aspect, the present invention provides compositions that modulate CCR4 activity. [0074]
  • Generally, the compositions will comprise a pharmaceutically acceptable excipient and a compound having the formula provided above as formula I: [0075]
    Figure US20020173524A1-20021121-C00009
  • wherein W is selected from aryl, heteroaryl, (C[0076] 1-C8)alkyl, heteroalkyl, cycloalkyl and heterocycloalkyl; X is selected from N(R5), S, O, C(R3)═C(R4), N═C(R4), and optionally, when Z is N, X can be C(R6)(R7); Y is selected from a bond, N(R5), N(R5)-(C1-C8)alkylene, O, S and S(O)n, wherein the integer n is 1 or 2; and Z is selected from N and C(R8). R1 and R2 are independently selected from H, halogen, CN, CO2R′, CONR′R″, (C1-C8)alkyl, heteroalkyl, aryl, heteroaryl, N(R6)(R7), OR9 and optionally, R1 and R2 combine to form a 5- to 8-membered ring containing from 0 to 3 heteroatoms selected from N, O and S, wherein R′ and R″ are independently selected from H, (C1-C8)alkyl and aryl. When R′ and R″ are attached to nitrogen, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. R3, R4 and R8 are independently selected from H, halogen, CN, OH, (C1-C8)alkyl, heteroalkyl, aryl, heteroaryl, O(C1-C8)alkyl, N(R6)(R7) and OR9; R5 is selected from H, (C1-C8)alkyl, heteroalkyl, aryl and heteroaryl; R6 and R7 are independently selected from H, (C1-C8)alkyl, heteroalkyl, aryl and heteroaryl; and R9 is selected from (C1-C8)alkyl, heteroalkyl and haloalkyl.
  • Preferred compounds useful in the present compositions are those of formula I in which W is selected from substituted naphthyl, pyridyl quinolyl, (C[0077] 1-C8)alkyl, heteroalkyl, cycloalkyl and heterocycloalkyl; X is selected from N(R5), S, O, C(R3)═C(R4), N═C(R4), and optionally, when Z is N, X can be C(R6)(R7); Y is selected from a bond, N(R5), N(R5)-(C1-C8)alkylene, O, S and S(O)n, wherein the integer n is 1 or 2; and Z is selected from N and C(R8). R1 and R2 are independently selected from H, halogen, CN, CO2R′, CONR′R″, (C1-C8)alkyl, heteroalkyl, aryl, heteroaryl, N(R6)(R7), OR9 and optionally, R1 and R2 combine to form a 5- to 8-membered ring containing from 0 to 3 heteroatoms selected from N, O and S, wherein R′ and R″ are independently selected from H, (C1-C8)alkyl and aryl. When R′ and R″ are attached to nitrogen, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. R3, R4 and R8 are independently selected from H, halogen, CN, OH, (C1-C8)alkyl, heteroalkyl, aryl, heteroaryl, O(C1-C8)alkyl, N(R6)(R7) and OR9; R5 is selected from H, (C1-C8) alkyl, heteroalkyl, aryl and heteroaryl; R6 and R7 are independently selected from H, (C1-C8)alkyl, heteroalkyl, aryl and heteroaryl; and R9 is selected from (C1-C8)alkyl, heteroalkyl and haloalkyl.
  • Additional compounds useful in the present invention are those having the general formula: [0078]
  • Ar1—X—Ar2   (II)
  • In formula II, the symbols Ar[0079] 1 and Ar2 each independently represent a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a substituted or unsubstituted fused aryl-heterocyclic ring system. The letter X represents a linking group selected from the group consisting of —N(R)—, —C(O)S—, —CH═CHSO2— and —SO2N(R)— wherein R is H or a substituted or unsubstituted (C1-C8)alkyl group. The linking group can be in either orientation relative to the Ar1 and Ar2 moieties. For example, the above general formula is meant to include both Ar1—SO2—NH—Ar2 and Ar1—NH—SO2—Ar2.
  • Returning to formula II above, in one group of preferred embodiments, Ar[0080] 1 is a substituted or unsubstituted heteroaryl group. Preferably Ar1 is a substituted or unsubstituted 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4 -pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, or 6-quinolyl group. More preferably, Ar1 is a substituted or unsubstituted thiazolyl, thienyl, benzoxadiazolyl or oxazolyl group.
  • In another group of preferred embodiments, Ar[0081] 2 is a substituted or unsubstituted aryl group. More preferably, Ar2 is a substituted or unsubstituted phenyl or naphthyl group. For those embodiments in which Ar2 is a substituted aryl group, there will preferably be from 1 to 4 substituents, independently selected from halogen, hydroxy, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkylthio, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, nitro, cyano, (C1-C4)acyl, amino, (C1-C4)alkylamino, and di(C1-C4)alkylamino. More preferably, there will be 1 to 3 substituents independently selected from halogen, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, nitro, cyano and (C1-C4)acyl. In the most preferred embodiments, Ar2 is a substituted or unsubstituted phenyl or naphthyl group. The substituted phenyl and napthyl groups will preferably have from 1 to 3 substituents independently selected from halogen, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, nitro, cyano and (C1-C4)acyl.
  • In another group of preferred embodiments, Ar[0082] 1 and Ar2 are each members independently selected from the group consisting of:
    Figure US20020173524A1-20021121-C00010
  • Further preferred are those embodiments in which Ar[0083] 1 is selected from substituted or unsubstituted phenyl or 2-naphthyl and Ar2 is selected from substituted or unsubstituted
    Figure US20020173524A1-20021121-C00011
  • In the most preferred embodiments, the compounds used in the present compositions are selected from: [0084]
    Figure US20020173524A1-20021121-C00012
  • Preparation of CCR4 Modulators of Formula II [0085]
  • A number of compounds useful as modulators of CCR4 signalling can be obtained from commercial sources such as Maybridge Chemical Co. and Aldrich Chemical Co. (Milwaukee, Wis., USA). [0086]
  • Other compounds can be prepared using conventional methods. For example, [0087] Scheme 1 illustrates the preparation of diarylsulfonamides (certain compounds of formula II).
    Figure US20020173524A1-20021121-C00013
  • In this scheme, an aryl (or heteroaryl) sulfonyl chloride i can be combined with a suitable aryl (or heteroaryl) amine ii to provide the target sulfonamides iii. The starting sulfonyl chlorides are typically prepared in one step from a sulfonic acid using a chlorinating agent such as POCl[0088] 3 or SOCl2. Similarly, starting arylamines ii are available from commercial sources or can be prepared in one step from the corresponding nitroaryl compounds.
  • In addition to the compounds provided above (of Formula I and Formula II), compositions for modulating chemokine receptor activity in humans and animals will typically contain a pharmaceutical carrier or diluent. [0089]
  • “Modulation” of chemokine receptor activity, as used herein in its various forms, is intended to encompass antagonism, agonism, partial antagonism and/or partial agonism of the activity associated with a particular chemokine receptor, preferably the CCR4 receptor. The term “composition” as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. By “pharmaceutically acceptable” it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. [0090]
  • The pharmaceutical compositions for the administration of the compounds of this invention may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. In the pharmaceutical composition the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases. [0091]
  • The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions. Such compositions may contain one or more agents selected from sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with other non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Pat. Nos. 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release. [0092]
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil. [0093]
  • Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxy-ethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin. [0094]
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid. [0095]
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present. [0096]
  • The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents. [0097]
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. [0098]
  • The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. [0099]
  • The compounds of the present invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols. [0100]
  • For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of the present invention are employed. As used herein, topical application is also meant to include the use of mouth washes and gargles. [0101]
  • The pharmaceutical composition and method of the present invention may further comprise other therapeutically active compounds as noted herein which are usually applied in the treatment of the above mentioned pathological conditions. [0102]
  • Methods of Treating CCR4-Mediated Conditions or Diseases [0103]
  • In yet another aspect, the present invention provides methods of treating or preventing a CCR4-mediated condition or disease by administering to a subject having such a condition or disease, a therapeutically effective amount of any compound of formula I above (e.g., without provisos) or a compound of formula II. Preferred compounds for use in the present methods are those compounds provided above as preferred embodiments, as well as compounds specifically exemplified in the Examples below, and provided with specific structures herein. The “subject” is defined herein to include animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like. In preferred embodiments, the subject is a human. [0104]
  • As used herein, the phrase “CCR4-mediated condition or disease” and related phrases and terms refer to a condition or disease characterized by inappropriate, e.g., less than or greater than normal, CCR4 functional activity. Inappropriate CCR4 functional activity might arise as the result of CCR4 expression in cells which normally do not express CCR4, increased CCR4 expression (leading to, e.g., inflammatory and immunoregulatory disorders and diseases) or decreased CCR4 expression. Inappropriate CCR4 functional activity might also arise as the result of TARC and/or MDC secretion by cells which normally do not secrete TARC and/or MDC, increased TARC and/or MDC expression (leading to, e.g., inflammatory and immunoregulatory disorders and diseases) or decreased TARC and/or MDC expression. A CCR4-mediated condition or disease may be completely or partially mediated by inappropriate CCR4 functional activity. However, a CCR4-mediated condition or disease is one in which modulation of CCR4 results in some effect on the underlying condition or disease (e.g., a CCR4 antagonist results in some improvement in patient well-being in at least some patients). [0105]
  • The term “therapeutically effective amount” means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician. [0106]
  • Diseases and conditions associated with inflammation, infection and cancer can be treated or prevented with the present compounds and compositions. In one group of embodiments, diseases or conditions, including chronic diseases, of humans or other species can be treated with inhibitors of CCR4 function. These diseases or conditions include: (1) allergic diseases such as systemic anaphylaxis or hypersensitivity responses, drug allergies, insect sting allergies and food allergies, (2) inflammatory bowel diseases, such as Crohn's disease, ulcerative colitis, ileitis and enteritis, (3) vaginitis, (4) psoriasis and inflammatory dermatoses such as dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria and pruritus, (5) vasculitis, (6) spondyloarthropathies, (7) scleroderma, (8) asthma and respiratory allergic diseases such as allergic asthma, allergic rhinitis, hypersensitivity lung diseases and the like, (9) autoimmune diseases, such as arthritis (including rheumatoid and psoriatic), multiple sclerosis, systemic lupus erythematosus, type I diabetes, glomerulonephritis, and the like, (10) graft rejection (including allograft rejection and graft-v-host disease), and (11) other diseases in which undesired inflammatory responses are to be inhibited, such as atherosclerosis, myositis, neurodegenerative diseases (e.g., Alzheimer's disease), encephalitis, meningitis, hepatitis, nephritis, sepsis, sarcoidosis, allergic conjunctivitis, otitis, chronic obstructive pulmonary disease, sinusitis, Behcet's syndrome and gout. [0107]
  • In another group of embodiments, diseases or conditions can be treated with agonists of CCR4 function. Examples of diseases to be treated with CCR4 agonists include cancers, diseases in which angiogenesis or neovascularization play a role (neoplastic diseases, retinopathy and macular degeneration), infectious diseases (viral infections, e.g., HIV infection, and bacterial infections) and immunosuppressive diseases such as organ transplant conditions and skin transplant conditions. The term “organ transplant conditions” is meant to include bone marrow transplant conditions and solid organ (e.g., kidney, liver, lung, heart, pancreas or combination thereof) transplant conditions. [0108]
  • Preferably, the present methods are directed to the treatment of diseases or conditions selected from allergic diseases, psoriasis, atopic dermatitis and asthma. [0109]
  • Depending on the disease to be treated and the subject's condition, the compounds of the present invention may be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV, intracisternal injection or infusion, subcutaneous injection, or implant), inhalation, nasal, vaginal, rectal, sublingual, or topical routes of administration and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration. The present invention also contemplates administration of the compounds of the present invention in a depot formulation. [0110]
  • In the treatment or prevention of conditions which require chemokine receptor modulation an appropriate dosage level will generally be about 0.001 to 100 mg per kg patient body weight per day which can be administered in single or multiple doses. Preferably, the dosage level will be about 0.01 to about 25 mg/kg per day; more preferably about 0.05 to about 10 mg/kg per day. A suitable dosage level may be about 0.01 to 25 mg/kg per day, about 0.05 to 10 mg/kg per day, or about 0.1 to 5 mg/kg per day. Within this range the dosage may be 0.005 to 0.05, 0.05 to 0.5 or 0.5 to 5.0 mg/kg per day. For oral administration, the compositions are preferably provided in the form of tablets containing 1.0 to 1000 milligrams of the active ingredient, particularly 1.0, 5.0, 10.0, 15.0. 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day. [0111]
  • It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy. [0112]
  • The compounds of the present invention can be combined with other compounds having related utilities to prevent and treat inflammatory conditions and diseases, including allergic diseases, psoriasis, atopic dermatitis and asthma, and those pathologies noted above. [0113]
  • For example, in the treatment or prevention of inflammation, the present compounds may be used in conjunction with an antiinflammatory or analgesic agent such as an opiate agonist, a lipoxygenase inhibitor, such as an inhibitor of 5-lipoxygenase, a cyclooxygenase inhibitor, such as a cyclooxygenase-2 inhibitor, an interleukin inhibitor, such as an interleukin-1 inhibitor, an NMDA antagonist, an inhibitor of nitric oxide or an inhibitor of the synthesis of nitric oxide, a non-steroidal antiinflammatory agent, or a cytokine-suppressing antiinflammatory agent, for example with a compound such as acetaminophen, aspirin, codeine, fentanyl, ibuprofen, indomethacin, ketorolac, morphine, naproxen, phenacetin, piroxicam, a steroidal analgesic, sufentanyl, sunlindac, tenidap, and the like. Similarly, the instant compounds may be administered with an analgesic listed above; a potentiator such as caffeine, an H2-antagonist (e.g., ranitidine), simethicone, aluminum or magnesium hydroxide; a decongestant such as phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxy-ephedrine; an antiitussive such as codeine, hydrocodone, caramiphen, carbetapentane, or dextromethorphan; a diuretic; and a sedating or non-sedating antihistamine. [0114]
  • Likewise, compounds and compositions of the present invention may be used in combination with other drugs that are used in the treatment, prevention, suppression or amelioration of the diseases or conditions for which compounds of the present invention are useful. Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of the present invention. When a compound of the present invention is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound of the present invention is preferred. Accordingly, the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients or therapeutic agents, in addition to a compound of the present invention. Examples of other therapeutic agents that may be combined with a compound of the present invention, either administered separately or in the same pharmaceutical compositions, include, but are not limited to: (a) VLA-4 antagonists, (b) corticosteroids, such as beclomethasone, methylprednisolone, betamethasone, prednisone, prenisolone, dexamethasone, fluticasone, hydrocortisone, budesonide, triamcinolone, salmeterol, salmeterol, salbutamol, formeterol; (c) immunosuppressants such as cyclosporine (cyclosporine A, Sandimmune®, Neoral®), tacrolimus (FK-506, Prograf®), rapamycin (sirolimus, Rapamune®) and other FK-506 type immunosuppressants, and mycophenolate, e.g., mycophenolate mofetil (CellCept®); (d) antihistamines (H1-histamine antagonists) such as bromopheniramine, chlorpheniramine, dexchlorpheniramine, triprolidine, clemastine, diphenhydramine, diphenylpyraline, tripelennamine, hydroxyzine, methdilazine, promethazine, trimeprazine, azatadine, cyproheptadine, antazoline, pheniramine pyrilamine, astemizole, terfenadine, loratadine, cetirizine, fexofenadine, descarboethoxyloratadine, and the like; (e) non-steroidal anti-asthmatics such as β2-agonists (e.g., terbutaline, metaproterenol, fenoterol, isoetharine, albuterol, bitolterol and pirbuterol), theophylline, cromolyn sodium, atropine, ipratropium bromide, leukotriene antagonists (e.g., zafirlukast, montelukast, pranlukast, iralukast, pobilukast and SKB-106,203), leukotriene biosynthesis inhibitors (zileuton, BAY-1005); (f) non-steroidal antiinflammatory agents (NSAIDs) such as propionic acid derivatives (e.g., alminoprofen, benoxaprofen, bucloxic acid, carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen, ibuprofen, indoprofen, ketoprofen, miroprofen, naproxen, oxaprozin, pirprofen, pranoprofen, suprofen, tiaprofenic acid and tioxaprofen), acetic acid derivatives (e.g., indomethacin, acemetacin, alclofenac, clidanac, diclofenac, fenclofenac, fenclozic acid, fentiazac, furofenac, ibufenac, isoxepac, oxpinac, sulindac, tiopinac, tolmetin, zidometacin and zomepirac), fenamic acid derivatives (e.g., flufenamic acid, meclofenamic acid, mefenamic acid, niflumic acid and tolfenamic acid), biphenylcarboxylic acid derivatives (e.g., diflunisal and flufenisal), oxicams (e.g., isoxicam, piroxicam, sudoxicam and tenoxican), salicylates (e.g., acetyl salicylic acid and sulfasalazine) and the pyrazolones (e.g., apazone, bezpiperylon, feprazone, mofebutazone, oxyphenbutazone and phenylbutazone); (g) cyclooxygenase-2 (COX-2) inhibitors such as celecoxib (Celebrex®) and rofecoxib (Vioxx®); (h) inhibitors of phosphodiesterase type IV (PDE-IV); (i) gold compounds such as auranofin and aurothioglucose, (j) etanercept (Enbrel®), (k) antibody therapies such as orthoclone (OKT3), daclizumab (Zenapax®), basiliximab (Simulect®) and infliximab (Remicade®), (l) other antagonists of the chemokine receptors, especially CCR1, CCR2, CCR3, CCR5, CCR6, CCR8 and CCR10; (m) lubricants or emollients such as petrolatum and lanolin, (n) keratolytic agents (e.g., tazarotene), (o) vitamin D[0115] 3 derivatives, e.g., calcipotriene or calcipotriol (Dovonex®), (p) PUVA, (q) anthralin (Drithrocreme®), (r) etretinate (Tegison®) and isotretinoin and (s) multiple sclerosis therapeutic agents such as interferon β-1β (Betaseron®), interferon β-1α (Avonex®), azathioprine (Imurek®, Imuran®), glatiramer acetate (Capoxone®), a glucocorticoid (e.g., prednisolone) and cyclophosphamide (t) other compounds such as 5-aminosalicylic acid and prodrugs thereof; hydroxychloroquine; D-penicillamine; antimetabolites such as azathioprine, 6-mercaptopurine and methotrexate; DNA synthesis inhibitors such as hydroxyurea and microtubule disrupters such as colchicine. The weight ratio of the compound of the present invention to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used. Thus, for example, when a compound of the present invention is combined with an NSAID the weight ratio of the compound of the present invention to the NSAID will generally range from about 1000:1 to about 1:1000, preferably about 200:1 to about 1:200. Combinations of a compound of the present invention and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.
  • In still other particularly preferred embodiments, the present methods are directed to the treatment of allergic diseases, wherein the compound of the invention is administered either alone or in combination with a second therapeutic agent, wherein said second therapeutic agent is an antihistamine. When used in combination, the practitioner can administer a combination of the therapeutic agents, or administration can be sequential. [0116]
  • In yet other particularly preferred embodiments, the present methods are directed to the treatment of psoriasis wherein the compound of the invention is used alone or in combination with a second therapeutic agent selected from a corticosteroid, a lubricant, a keratolytic agent, a vitamin D[0117] 3 derivative, PUVA and anthralin.
  • In particularly preferred embodiments, the present methods are directed to the treatment of atopic dermatitis using a compound of the invention either alone or in combination with a second therapeutic agent selected from a lubricant and a corticosteroid. [0118]
  • In particularly preferred embodiments, the present methods are directed to the treatment of asthma using a compound of the invention either alone or in combination with a second therapeutic agent selected from a β2-agonist and a corticosteroid. [0119]
  • Method of Evaluating Putative CCR4 Modulators [0120]
  • In yet another aspect, the present invention includes methods to evaluate putative specific agonists or antagonists of CCR4 function. Accordingly, the present invention is directed to the use of these compounds in the preparation and execution of screening assays for compounds which modulate the function of the CCR4 chemokine receptor. For example, the compounds of this invention are useful for isolating receptor mutants, which are excellent screening tools for potent compounds. Furthermore, the compounds of this invention are useful in establishing or determining the binding site of other compounds to the CCR4 chemokine receptor, e.g., by competitive inhibition. The compounds of the instant invention are also useful for the evaluation of putative specific modulators of the CCR4 chemokine receptor, relative to other chemokine receptors including CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR5, CCR6, CCR8, CCR10, CXCR3 and CXCR4. One of skill in the art will appreciate that thorough evaluation of specific agonists and antagonists of the above chemokine receptors has been hampered by the lack of availability of non-peptidyl (metabolically resistant) compounds with high binding affinity for these receptors. The compounds provided herein are particularly useful in this context. [0121]
  • Combinatorial libraries of putative CCR4 agonists or antagonists can be screened for pharmacological activity in in vitro or in vivo assays. Conventionally, new chemical entities with useful properties are generated by identifying a chemical compound (called a “lead compound”) with some desirable property or activity, e.g., CCR4 chemokine receptor modulation activity, creating variants of the lead compound, and evaluating the properties and activities of those variant compounds. However, the current trend is to shorten the time scale for all aspects of drug discovery. Because of the ability to test large numbers of compounds quickly and efficiently, high throughput screening (HTS) methods are replacing conventional lead compound identification methods. [0122]
  • In one preferred embodiment, high throughput screening methods involve providing a library containing a large number of potential therapeutic compounds (candidate compounds). Such “combinatorial chemical libraries” are then screened in one or more assays to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional “lead compounds” or can themselves be used as potential or actual therapeutics. [0123]
  • A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical “building blocks”, such as reagents. For example, a linear combinatorial chemical library, such as a polypeptide (e.g., mutein) library, is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks (Gallop et. al. (1994) [0124] J. Med. Chem. 37(9):1233-1251).
  • Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Pat. No. 5,010,175, Furka (1991) [0125] Int. J. Pept. Prot. Res. 37:487-493, Houghton et. al. (1991) Nature 354: 84-88), peptoid libraries (PCT Publication No WO 91/19735), encoded peptide libraries (PCT Publication WO 93/20242), random bio-oligomer libraries (PCT Publication WO 92/00091), benzodiazepine libraries (U.S. Pat. No. 5,288,514), libraries of diversomers, such as hydantoins, benzodiazepines and dipeptides (Hobbs et. al. (1993) Proc. Nat. Acad. Sci. USA 90:6909-6913), vinylogous polypeptide libraries (Hagihara et al. (1992) J. Amer. Chem. Soc. 114:6568), libraries of nonpeptidyl peptidomimetics with a Beta-D-Glucose scaffolding (Hirschmann et al (1992) J. Amer. Chem. Soc. 114:9217-9218), analogous organic syntheses of small compound libraries (Chen et. al. (1994) J. Am. Chem. Soc. 116:2661), oligocarbamate libraries (Cho et al. (1993) Science 261:1303) and/or peptidyl phosphonate libraries (Campbell et al. (1994) J. Org. Chem. 59:658). See, generally, Gordon et al. (1994) J. Med. Chem. 37:1385-1401, nucleic acid libraries (see, e.g., Stratagene Corp.), peptide nucleic acid libraries (see, e.g., U.S. Pat. No. 5,539,083), antibody libraries (see, e.g., Vaughn et. al. (1996) Nature Biotechnology 14(3):309-314), and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang et al. (1996) Science 274:1520-1522, and U.S. Pat. No. 5,593,853), and small organic molecule libraries (see, e.g., benzodiazepines, Baum (1993) C&EN January 18, page 33 and U.S. Pat. No. 5,288,514; isoprenoids, U.S. Pat. No. 5,549,974; pyrrolidines, U.S. Pat. Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Pat. No. 5,506,337; and the like).
  • Devices for the preparation of combinatorial libraries are commercially available (see, e.g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville Ky.; Symphony, Rainin, Woburn Mass.; 433A Applied Biosystems, Foster City Calif.; 9050 Plus, Millipore, Bedford, Mass.). [0126]
  • A number of well known robotic systems have also been developed for solution phase chemistries. These systems includes automated workstations like the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate II, Zymark Corporation, Hopkinton Mass.; Orca, Hewlett-Packard, Palo Alto Calif.), which mimic the manual synthetic operations performed by a chemist. Any of the above devices are suitable for use with the present invention. The nature and implementation of modifications to these devices (if any) so that they can operate as discussed herein will be apparent to persons skilled in the relevant art. In addition, numerous combinatorial libraries are themselves commercially available (see e.g., ComGenex, Princeton N.J.; Asinex, Moscow, Russia; Tripos, Inc., St. Louis Mo.; ChemStar, Ltd, Moscow, Russia; 3D Pharmaceuticals, Exton Pa.; Martek Biosciences, Columbia Md.; etc.). [0127]
  • High throughput assays for the presence, absence, quantification, or other properties of particular compounds may be used to test a combinatorial library that contains a large number of potential therapeutic compounds (potential modulator compounds). The assays are typically designed to screen large chemical libraries by automating the assay steps and providing compounds from any convenient source to the assays, which are typically run in parallel (e.g., in microtiter formats on microtiter plates in robotic assays). Preferred assays detect enhancement or inhibition of CCR4 receptor function. [0128]
  • High throughput screening systems are commercially available (see e.g., Zymark Corp., Hopkinton Mass.; Air Technical Industries, Mentor Ohio; Beckman Instruments, Inc., Fullerton Calif.; Precision Systems, Inc., Natick Mass.; etc.). These systems typically automate entire procedures, including all sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detector(s) appropriate for the assay. These configurable systems provide high throughput and rapid start-up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for various high throughput systems. Thus, for example, Zymark Corp. provides technical bulletins describing screening systems for detecting the modulation of gene transcription, ligand binding, and the like. [0129]
  • Other Evaluation Assays for CCR4 Modulators [0130]
  • A variety of assays can be used to evaluate the compounds provided herein, including CCR4 binding assays, CCR4 signalling assays, chemotaxis assays, and other assays of cellular response. [0131]
  • In a suitable assay, a CCR4 protein (whether isolated or recombinant) is used which has at least one property, activity or functional charateristic of a mammalian CCR4 protein. The property can be a binding property (to, for example, a ligand or inhibitor), a signalling activity (e.g., activation of a mammalian G protein, induction of rapid and transient increase in the concentration of cytosolic free calcium [Ca[0132] ++]i), cellular response function (e.g., stimulation of chemotaxis or inflammatory mediator release by leukocytes), and the like.
  • In one embodiment, a composition containing a CCR4 protein or variant thereof is maintained under conditions suitable for binding. The CCR4 receptor is contacted with a putative agent (or a second composition containing at least one putative agent) to be tested, and binding is detected or measured. [0133]
  • In one group of preferred embodiments, the assay is a cell-based assay and cells are used which are stably or transiently transfected with a vector or expression cassette having a nucleic acid sequence which encodes the CCR4 receptor. The cells are maintained under conditions appropriate for expression of the receptor and are contacted with a putative agent under conditions appropriate for binding to occur. Binding can be detected using standard techniques. For example, the extent of binding can be determined relative to a suitable control (for example, relative to background in the absence of a putative agent, or relative to a known ligand). Optionally, a cellular fraction, such as a membrane fraction, containing the receptor can be used in lieu of whole cells. [0134]
  • Detection of binding or complex formation can be detected directly or indirectly. For example, the putative agent can be labeled with a suitable label (e.g., fluorescent label, chemiluminescent label, isotope label, enzyme label, and the like) and binding can be determined by detection of the label. Specific and/or competitive binding can be assessed by competition or displacement studies, using unlabeled agent or a ligand (e.g., TARC or MDC) as a competitor. [0135]
  • In other embodiments, binding inhibition assays can be used to evaluate the present compounds. In these assays, the compounds are evaluated as inhibitors of ligand binding using, for example, TARC or MDC. In this embodiment, the CCR4 receptor is contacted with a ligand such as TARC or MDC and a measure of ligand binding is made. The receptor is then contacted with a test agent in the presence of a ligand (e.g., TARC or MDC) and a second measurement of binding is made. A reduction in the extent of ligand binding is indicative of inhibition of binding by the test agent. The binding inhibition assays can be carried out using whole cells which express CCR4, or a membrane fraction from cells which express CCR4. [0136]
  • The binding of a G protein-coupled receptor by, for example, an agonist, can result in a signalling event by the receptor. Accordingly, signalling assays can also be used to evaluate the compounds of the present invention and induction of signalling function by an agent can be conitored using any suitable method. For example, G protein activity, such as hydrolysis of GTP to GDP, or later signalling events triggered by receptor binding can be assayed by known methods (see, for example, PCT/US97/15915; Neote, et al., [0137] Cell, 72:415-425 (1993); Van Riper, et al., J. Exp. Med., 177:851-856 (1993) and Dahinden, et al, J. Exp. Med., 179:751-756 (1994)).
  • Chemotaxis assays can also be used to assess receptor function and evaluate the compounds provided herein. These assays are based on the functional migration of cells in vitro or in vivo induced by an agent, and can be used to assess the binding and/or effect on chemotaxis of ligands, inhibitors, or agonists. Suitable assays are described in PCT/US97/15915; Springer, et al., WO 94/20142; Berman et al., [0138] Immunol. Invest., 17:625-677 (1988); and Kavanaugh et al., J. Immunol., 146:4149-4156 (1991)).
  • The compounds provided herein can also be evaluated using models of inflammation to assess the ability of the compound to exert an effect in vivo. Suitable models are described as follows: a sheep model for asthma (see, Weg, et al., [0139] J. Exp. Med., 177:561 (1993)); and a rat delayed-type hypersensitivity model (see Rand, et al., Am. J. Pathol., 148:855-864 (1996)). Another useful model for evaluating the instant compounds is the experimental autoimmune encephalomyelitis (EAE) model for multiple sclerosis, which probes chemokine receptor expression and function (see, Ransohoff, et al., Cytokine Growth Factor Rev., 7:35-46 (1996), and Karpus, et al., J. Immunol. 161:2667-2671 (1998)).
  • In addition, leukocyte infiltration assays can also be used to evaluate a compound (see, Van Damme, et al., [0140] J. Exp. Med. 176:59-65 (1992); Zachariae, et al., J. Exp. Med. 171:2177-2182 (1990); and Jose, et al., J. Exp. Med. 179:881-887 (1994)).
  • The following examples are offered to illustrate, but not to limit the claimed invention. [0141]
    • EXAMPLES
  • Reagents and solvents used below can be obtained from commercial sources such as Aldrich Chemical Co. (Milwaukee, Wis., USA). [0142] 1H-NMR spectra were recorded on a Varian Gemini 400 MHz NMR spectrometer. Significant peaks are tabulated in the order: number of protons, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br s, broad singlet) and coupling constant(s) in Hertz (Hz). Electron Ionization (El) mass spectra were recorded on a Hewlett Packard 5989A mass spectrometer. Mass spectrometry results are reported as the ratio of mass over charge, followed by the relative abundance of each ion (in parentheses). In tables, a single m/e value is reported for the M+H (or, as noted, M−H) ion containing the most common atomic isotopes. Isotope patterns correspond to the expected formula in all cases. Electrospray ionization (ESI) mass spectrometry analysis was conducted on a Hewlett Packard 1100 MSD electrospray mass spectrometer using the HP1 100 HPLC for sample delivery. Normally the analyte was dissolved in methanol at 0.1 mg/mL and 1 microliter was infused with the delivery solvent into the mass spectrometer, which scanned from 100 to 1500 daltons. All compounds could be analyzed in the positive ESI mode, using 1:1 acetonitrile/water with 1% acetic acid as the delivery solvent. The compounds provided below could also be analyzed in the negative ESI mode, using 2 mM NH4OAc in acetonitrile/water as delivery solvent.
    • General Procedures
  • [0143]
    Figure US20020173524A1-20021121-C00014
    • General Procedures
  • [0144]
    Figure US20020173524A1-20021121-C00015
  • General Procedure for Preparing Aryl Thioureas [0145]
  • To a solution of aryl amine (4.1 mmol) in dry acetone (30 mL) at room temperature was added dropwise benzoylisothiocyanate (0.56 mL, 4.5 mmol). After 1 h, the reaction mixture was concentrated in vacuo to afford a solid compound, which was triturated with 50% aqueous ethanol (50 mL) to dissolve inorganic materials. The crude product was stirred with 20 mL of 10% NaOH at 98° C. for 10 min. After cooling, the basic solution was neutralized by adding 10% HCI solution. The precipitate was filtered and then washed with water. [0146]
  • General Procedure for Preparing 2-Amino-4-Alkyl-Substituted Thiazoles [0147]
    Figure US20020173524A1-20021121-C00016
  • [0148] Procedure 1
  • To a solution of N-arylthiourea or N-benylthiourea (1 mmol) in methanol (5 mL) at room temperature was added α-haloketone (1.05 mmol). The reaction mixture was refluxed for 3 h and then concentrated in vacuo. The crude compound was then recrystalized with ethyl ether and methylene chloride to afford 2-aminothiazole as the salt form. [0149]
  • [0150] Procedure 2
  • To a boiling suspension of N-arylthiourea (1.0 mmol) and MgSO[0151] 4 (60 mg) in acetone (6.0 mL) was added a solution of α-haloketone (1.1 mmol) in acetone (1.0 mL) dropwise. The reaction mixture was refluxed for 2 to 8 h. The mixture was then cooled to room temperature, poured into a saturated solution of brine (5 mL). The solution was then basified with concentrated NH4OH aqueous solution, diluted with water (5 mL) and then extracted with EtOAc (2×20 mL). The organic layers were combined, dried over anhydrous MgSO4 and concentrated in vacuo. The crude product was purified by silica gel flash column chromatography (ethyl acetate and hexanes).
  • In some cases, the desired thiazole products were precipitated from reaction solution. The isolation was then carried out by filtration through a Bückner funnel and washed the solid with acetone. The final products were isolated as the salt forms. [0152]
    • Example 1
  • [0153]
    Figure US20020173524A1-20021121-C00017
  • [0154] 1H NMR (400 MHz, CDCl3):δ 7.4-7.5 (m, 1H), 7.3-7.4 (m, 2H), 7.2-7.3 (m, 1H), 6.17 (s, 1H), 4.04 (m, 4H), 2.96 (m, 4H), 1.47 (s, 9H); MS (ES+): 318.2 (M+H).
    • Example 2
  • [0155]
    Figure US20020173524A1-20021121-C00018
  • [0156] 1H NMR (400 MHz, CDCl3):δ 11.2(s, br, 1H), 7.1-7.2 (m, 3H), 6.04 (s, 1H), 2.35 (s, 3H), 1.57 (s, 3H), 1.44 (s, 9H). MS (ES+): 261.1 (M+H).
    • Example 3
  • [0157]
    Figure US20020173524A1-20021121-C00019
  • [0158] 1H NMR (400 MHz, CDCl3):δ 10.1 (s, br, 1H), 7.3-7.4 (m, 5H), 6.01 (s, 1H), 4.51 (s, 2H), 1.39 (s, 9H). MS (ES+): 247.1 (M+H).
    • Example 4
  • [0159]
    Figure US20020173524A1-20021121-C00020
  • [0160] 1H NMR (400 MHz, CDCl3):δ 12.0 (s, br, 1H), 8.3-8.4 (m, 2H), 7.7-7.8 (m, 2H), 7.63 (d, J=8.1 Hz, 1H), 7.53 (d, J=8.1 Hz, 1H), 6.13 (s, 1H), 1.44 (s, 9H). MS (ES+): 317.1 (M+H).
    • Example 5
  • [0161]
    Figure US20020173524A1-20021121-C00021
  • [0162] 1H NMR (400 MHz, CDCl3):δ 7.1-7.2 (m, 3H), 6.14 (s, 1H), 2.82 (t, J=6 Hz, 2H), 2.77 (t, J=6 Hz, 2H), 1.8-1.9 (m, 4H), 1.41 (s, 9H). MS (ES+): 287.1 (M+H).
    • Example 6
  • [0163]
    Figure US20020173524A1-20021121-C00022
  • [0164] 1H NMR (400 MHz, CDCl3):δ 11.46 (s, br, 1H), 7.60 (d, J=8 Hz, 1H), 7.36 (d, J=8 Hz, 1H), 7.17 (t, J=8 Hz, 1H), 6.11 (s, 1H), 2.54 (s, 3H), 1.44 (s, 9H). MS (ES+): 325.1 (M+H).
    • Example 7
  • [0165]
    Figure US20020173524A1-20021121-C00023
  • [0166] 1H NMR (400 MHz, CDCl3):δ 9.34 (s, br, 1H), 9.23 (d, J=8.5 Hz, 1H), 8.49 (d, J=8.1 Hz, 1H), 7.9-8.1 (m, 3H), 6.23 (s, 1H), 1.46 (s, 9H). MS (ES+): 284.1 (M+H).
    • Example 8
  • [0167]
    Figure US20020173524A1-20021121-C00024
  • To a solution of 4,4-dimethyl-2-pentanone (0.25 mL, 1.7 mmol) in methanol (10 mL) was added bromine (0.09 mL, 1.7 mmol) in methanol (3 mL) dropwise at 0° C. The reaction mixture was warmed up from 0° C. to room temperature, and kept at room temperature for 1 h. 1-Naphthylthiourea (0.35 g, 1.7 mmol) was then added to the reaction mixture and refluxed for 3 h. The reaction mixture was concentrated in vacuo. The crude compound was recrystalized with ethyl ether and methylene chloride to afford 2-aminothiazole as the HBr salt. [0168] 1H-NMR (400 MHz, CDCl3):δ 8.12 (d, J=8.1 Hz, 1H), 7.8-8.0 (m, 2H), 7.1-7.7 (m, 4H), 6.04 (s, 1H), 2.76 (s, 2H), 1.44 (s, 9H). MS (ES+): 297.2 (M+H).
    • Example 9
  • [0169]
    Figure US20020173524A1-20021121-C00025
  • [0170] 1H NMR (400 MHz, CDCl3):δ 12.6 (s, br, 1H), 8.41 (d, J=8.1 Hz, 1H), 7.91 (dd, J=8.1, 21 Hz, 2H), 7.5-7.7 (m, 4H), 2.73 (t, J=8 Hz, 2H), 1.5-1.6 (m, 2H), 1.55 (s, 9H), 1.0 (t, J=8 Hz, 3H). MS (ES+): 325.2 (M+H).
    • Example 10
  • [0171]
    Figure US20020173524A1-20021121-C00026
  • [0172] 1H NMR (400 MHz, CDCl3):δ 13.6 (s, br, 1H), 8.12 (d, J=8.1 Hz, 1H), 7.91 (dd, J=8.1, 21 Hz, 2H), 7.4-7.6 (m, 4H), 2.27 (s, 3H), 1.49 (s, 9H) MS (ES+): 297.2 (M+H).
    • Example 11
  • [0173]
    Figure US20020173524A1-20021121-C00027
  • [0174] 1H NMR (400 MHz, CDCl3): δ 11.02 (s, 1H), 8.09-8.07 (m, 1H), 7.92-7.89 (m, 1H), 7.82 (d, J=7.5 Hz, 1H), 7.69 (d, J=8.3 Hz, 1H), 7.58-7.53 (m, 2H), 7.50 (dd, J =7.8, 7.8 Hz, 1H), 6.21 (s, 1H), 1.37 (s, 9H); MS (ES+): 283.1 (M+H).
    • Example 12
  • [0175]
    Figure US20020173524A1-20021121-C00028
  • [0176] 1H NMR (400 MHz, CDCl3): δ 8.10 (d, J=9.4 Hz, 1H), 7.91 (dd, J=9.4, 2.7 Hz, 1H), 7.73 (d, J=7.7 Hz, 2H), 7.55-7.28 (m, 3H), 6.14 (s, 1H), 2.95 (septet, J=6.9 Hz, 1H), 6.9 (d, J=6.9 Hz, 6H); MS (ES+) 269.1 (M+H).
    • Example 13
  • [0177]
    Figure US20020173524A1-20021121-C00029
  • [0178] 1H NMR (400 MHz, CDCl3): δ 8.06 (dd, J=6.3, 3.5 Hz, 1H), 7.92-7.89 (m, 1H), 7.81 (d, J=7.5 Hz, 1H), 7.69 (d, J=8.3 Hz, 1H), 7.53 (dd, J=6.3, 3.2 Hz, 2H), 7.49 (dd, J=7.8, 7.8 Hz, 1H), 6.25 (s, 1H), 4.09 (q, J=7.1 Hz, 2H), 2.72 (s, 2H), 1.46 (s, 6H), 1.21 (t, J=7.1 Hz, 3H); MS (ES+) 355.1 (M+H).
    • Example 14-15
  • [0179]
    Figure US20020173524A1-20021121-C00030
  • A mixture of 14 (70 mg, 0.22 mmol, prepared from 1,3-dichloroacetone and N-naphthylthiourea following general procedure 2) and diisopropylamine (129 mg, 1.0 mmol) in ethanol (1.5 mL) was stirred at reflux for 6 h. After evaporating ethanol the crude product was purified by HPLC to afford the desired product (TFA salt) as colorless liquid (33 mg, 40% yield). [0180] 1H-NMR (400 MHz, CDCl3): δ11.1 (s, 1H), 8.05-8.03 (m, 1H), 7.96-7.94 (m, 1H), 7.87 (d, J=8.3, 1H), 7.69 (dd, J=8.3, 0.9 Hz, 1H), 7.65-7.59 (m, 2H), 7.53 (dd, J=7.8, 7.8 Hz, 1H), 7.06 (s, 1H), 4.37 (s, 2H), 3.00 (d, J=6.7 Hz, 4H), 2.20-2.11 (m, 2H), 1.09 (d, J=6.7 Hz, 12H). MS (ES+) 368.3 (M+H).
    • Examples 16-18
  • [0181]
    Figure US20020173524A1-20021121-C00031
    • Example 16
  • Compound 16 was prepared from N-naphthylthiourea (606 mg, 3.0 mmol) and 1-bromo-2,3-butanedione (4.0 mmol) according to [0182] general procedure 2. This material was carried to the next step without further purification.
    • Example 17
  • To a stirred suspension of 4-acetoyl-2-naphthylamino thiazole (65 mg, 0.18 mmol) and iso-butylamine (53 mg, 0.72 mmol) in methanol (3 mL) was added a solution of sodium cyanoborohydride (30 mg) in methanol (1 mL) at 0° C. After stirring the mixture for 12 h, it was diluted with EtOAc (20 mL) and washed with water (2×5 mL). The organic layer was dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by HPLC to give 4-iso-butylamino-2′-ethyl-2-naphthylaminothiazole (17) as white solid (27 mg, 45% yield). [0183]
    • Example 18
  • Compound 18 was prepared from 4-iso-butylamino-2′-ethyl-2-naphthylamino thiazole and iso-butylaldehyde according to the general procedure of reductive amination outlined above. Purification of the crude product by HPLC afforded the desired product as white solid (61 mg, 50% yield). [0184] 1H-NMR (400 MHz, CDCl3): δ 7.97-7.95 (m, 1H), 7.83-7.81 (m, 1H), 7.68-7.62 (m, 2H), 7.47-7.45 (m, 2H), 7.39 (dd, J=7.8, 7.8 Hz, 1H), 6.64 (s, 1H), 4.53 (q, J=6.7 Hz, 1H), 2.92 (m, 2H), 2.66 (m, 2H) 1.96 (m, 2H), 1.59 (d, J=6.7 Hz, 3H), 0.94 (d, J=6.6 Hz, 6H), 0.80 (d, J=6.6 Hz, 6H); MS (ES+) 382.3 (M+H).
    • Example 19
  • [0185]
    Figure US20020173524A1-20021121-C00032
  • A mixture of 1-aminonaphthalene (2.0 mmol, 268 mg) and 2,6-dichlorobenzenethiazole (1.0 mmol, 203 mg) in DMF (3.0 mL) was heated at 110° C. for 8 h. The mixture was allowed to cool to room temperature, diluted with EtOAc (15.0 mL) and then extracted with H[0186] 2O (4×10 mL) to remove DMF. The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexanes/EtOAc) to afford the desired product as yellow solid (124 mg, 40% yield). 1H-NMR (400 MHz, CDCl3): δ7.87-7.83 (m, 4H), 7.51-7.49 (m, 2H), 7.36-7.33 (m, 2H), 6.82 (dd, J=6.8, 1.5Hz, 2H). MS (ES+) 311.0 (M+H).
    • Example 20
  • [0187]
    Figure US20020173524A1-20021121-C00033
  • This compound was prepared from 1-benzyl-3-bromo-4-piperidone (which is synthesized from 1-benzyl-4-piperidone by regioselective bromination) and N-naphthylthiourea following a general procedure. Purification of the crude product by HPLC gave (20) as white solid (178 mg, 48% yield). [0188] 1H NMR (400 MHz, CDCl3): δ 7.89 (d, J=9.1 Hz, 1H), 7.87 (d, J=8.4 Hz, 1H), 7.73-7.68 (m, 2H), 7.58-7.41 (m, 4H), 7.32-7.21 (m, 4H), 3.49 (s, 2H), 3.14 (s, 2H), 2.68 (t, J=5.4 Hz, 2H), 2.60 (t, J=5.4 Hz, 2H); MS (ES+) 372.2 (M+H).
    • Example 21
  • This example illustrates a CCR4 binding assay that can be used for evaluating the compounds of the present invention. [0189]
  • Detection of radiolabelled TARC and/or MDC binding to CCR4 [0190]
  • [0191] 125I-labelled TARC and MDC are available from commercial sources (e.g., Amersham-Pharmacia or Perkin Elmer Life Sciences). All buffers and materials are available from commercial sources (e.g., Gibco BRL, Sigma). To measure binding of 125I-TARC or 125I-MDC to cells expressing CCR4 (e.g., CEM cells, available from the ATCC), the 125I-TARC or 125I-MDC is diluted to a concentration of approximately 200 pM in a buffered saline solution (e.g., RPMI supplemented with 0.5% bovine serum albumin), and added to an equal volume of a suspension of cells (e.g., CEM cells at 5×106 cells/mL). The resulting mixture is incubated for a period of time (e.g., 2 hours). The unbound 125I-TARC or 125I-MDC is separated from the cells by filtration, e.g., by passage through GF/B filter plate (Packard Biosciences) pre-treated with 0.3% polyethyleneimine (Sigma), using a Packard Filtermate 96 (Packard Biosciences). The amount of 125I-TARC or 125I-MDC retained with the cells on the filterplate is measured by adding a small amount of scintillation fluid (e.g., 50 μL of Microscint-20, obtained from Packard Biosciences), and reading scintillation on appropriate detection equipment, e.g., a Packard TopCount 383 (Packard Biosciences).
  • Non-specific binding of [0192] 125I-TARC or 125I-MDC can be estimated by measuring the amount of 125I-TARC or 125I-MDC retained with the cells on the filterplate when the assay is performed in the presence of a large excess of unlabelled TARC or MDC.
  • Inhibition of [0193] 125I-TARC or 125I-MDC binding to CCR4 is defined as a decrease in the retention of 125I-TARC or 125I-MDC to the cells on the filterplate.
  • The assay described above varies only moderately from standardly used procedures, e.g., Imai et al. (1997) [0194] J. Biol. Chem. 272:15036-15042, Imai et al. (1998) J. Biol. Chem. 273:1764-1768.
    TABLE 1
    CCR4 antagonist activity for compounds of the invention
    (inhibition of 125I-TARC binding).
    Compound IC50 (nM)
    12 +
    2 +
    11 +
    4 ++
    9 +
    10 +
    1 ++
    3 ++
    13 +
    5 +
    19 ++
    8 +
    15 +
    6 +
    18 +
    7 ++
    20 +
    • EXAMPLE 22
  • This example illustrates additional screening procedures used in characterizing the compounds of the present invention. [0195]
  • Source plates of chemical libraries were obtained from commercial vendors and contained individual compounds at 5 mg/mL in DMSO, or in some instances, at 1 mg/nL. From these, multiple compound plates containing 10 compounds in each well were made, and these were diluted in 20% DMSO to a concentration of 50 μg/mL (10 μg/mL for those beginning at 1 mg/mL). An aliquot of 20 μL of each mixture was put into the test plates, which were stored frozen until use. [0196]
  • A CCR4 expressing stable transfectant cell line was prepared using current standard molecular biological methods. The CCR4 transfectants were cultured in IMDM-5% FBS, and harvested when the concentration was between 0.5-1.0×10[0197] 6 cells/ml. The cells were centrifuged and resuspended in assay buffer (20 mM HEPES pH 7.1, 140 mM NaCl, 1 mM CaCl2, 5mM MgCl2, and with 0.2% bovine serum albumin) to a concentration of 5.6×106 cells/ml. To set up the screening assays, first 0.09 ml of cells was added to the assay plates containing the compounds. (For a final compound concentration of 1-5 μg/ml each [˜2-10 μM]). Then 0.09 ml of 125I labeled MDC or TARC diluted in assay buffer (final concentration ˜50 pM, with ˜30,000 cpm per well) was added. The plates were sealed and incubated for approximately 3 hours at 4° C. on a shaker platform. The assay plates were harvested using Packard filter plates, pre-soaked in 0.3% PEI (polyethyleneimine) solution, on a Packard vacuum cell harvester. Scintillation fluid (50 μl) was added to all wells and the plates were sealed and counted in a Top Count scintillation counter. Control wells containing either diluent only (for total counts) or excess MDC or TARC (1 μg/ml, for non-specific binding) were used to calculate the percent of total inhibition for each set of compounds. Further tests on individual compounds were carried out in the same manner. IC50 values are those concentrations required to reduce the binding of labeled MDC or TARC to the receptor by 50%.
  • The calcium mobilization experiments were performed by labeling the human T-cell line CEM with NDO-1 dye (45 min at room temperature), washing with PBS, and resuspending into flux buffer (HBSS with 1% fetal bovine serum). For each test, 1×10[0198] 6 cells were incubated at 37° C. in the cuvette of a PTI spectrometer, and the ratio of 410/490 nm emission plotted over time (typically 2-3 minutes), with compounds added at 5 seconds, followed by MDC, TARC or other chemokines.
  • Chemotaxis assays were performed using 5 μ filter plates (Neuroprobe) with the chemoattractant (MDC, TARC, or SDF) placed in the lower chamber, and a cell suspension of 100,000 CEM cells in the upper chamber. The assays were incubated 1-2 hours at 37° C., and the number of cells in the lower chamber quantified by the CyQuant assay (Molecular Probes). [0199]
  • Results are provided in Figures. [0200]
    • EXAMPLE 23
  • This example describes a procedure to evaluate the efficacy of CCR4 antagonists for treatment of septic shock. [0201]
  • An animal model of endotoxic shock can be induced by injecting rodents with lipopolysaccharide (LPS). Three series of mouse groups, comprising 15 mice per group, are treated with an intra-peritoneal injection of an L.D.(lethal dose)-90 of LPS (precise dose requires titration of the particular batch of lipopolysaccharide in the actual mouse colony in use to determine a re-producible dose of LPS that produces 90% mortality in mice). One series of mice additionally receives phosphate buffered saline (PBS) and Tween 0.5% i.p. 30 minutes before LPS administration. A second series consists of groups of mice receiving different doses of the CCR4 antagonist(s) given either intra-peritoneally, intra-venously, sub-cutaneously, intramuscularly, orally, or via any other mode of administration 30 minutes before, or concurrently with, LPS administration. A third series of mice, serving as positive control, consists of groups treated with either mouse IL-10 i.p., or anti-TNF antibodies i.p., 30 minutes before LPS administration. [0202]
  • Mice are monitored for death for 72 hours following the LPS injection. [0203]
    • EXAMPLE 24
  • This example describes a procedure to evaluate the efficacy of CCR4 antagonists for treatment of asthma. [0204]
  • An animal model of asthma can be induced by sensitizing rodents to an experimental antigen (e.g. OVA) by standard immunization, and then subsequently introducing that same antigen into the rodents lung by aerosolization. Three series of rodent groups, comprising 10 rodents per goup, are actively sensitized on [0205] Day 0 by a single intraperitoneal injection with 100 ug OVA in phosphate-buffered saline (PBS), along with an IgE-selective adjuvant e.g. aluminum hydroxide. At 11 days after sensitization, at the peak of their IgE response, the animals are placed in a Plexiglas chamber and challenged with aerosolized OVA (1%) for 30 minutes using the ultrasonic nebulizer (De Vilbliss). One series of mice additionally receives phosphate buffered saline (PBS)and Tween 0.5% i.p. at the initial sensitization, and at different dosing schedules thereafter, up until the aerosolized OVA challenge. A second series consists of groups of mice receiving different doses of the CCR4 antagonist(s) given either intra-peritoneally, intra-venously, sub-cutaneously, intra-muscularly, orally, or via any other mode of administration at the initial sensitization, and at different dosing schedules thereafter, up until the aerosolized OVA challenge. A third series of mice, serving as positive control, consists of groups treated with either mouse IL-10 i.p., anti-IL4 antibodies i.p., or anti-IL5 antibodies i.p. at the initial sensitization, and at different dosing schedules thereafter, up until the aerosolized OVA challenge.
  • Animals were subsequently analyzed at different time points after the aerosolized OVA challenge for pulmonary function, cellular infiltrates in bronchoalveolar lavage (BAL), histological examination of lungs, and measurement of serum OVA-specific IgE titers. [0206]
    • EXAMPLE 25
  • This example describes a procedure to evaluate the efficacy of CCR4 antagonists for augmenting protective immunity against viruses, bacteria and parasites. [0207]
  • Protective immunity to microbial pathogens is frequently mediated by Th1 regulatory T cells. Since CCR4 antagonists are likely inhibitors of Th2 regulatory cells, they may alter the cross regulation that normally exists between Th1 and Th2 cells, and potentiate Th1 cells, thereby augmenting protection against infectious disease. Three series of mouse groups, comprising 15 mice per group, are infected with the intracellular parasite [0208] Leishmania major(L.major) by injecting L.major promastigotes sub-cutaneously into their left hind footpads. Four weeks after infection, the animals are challenged with either Leishmania freeze-thawed antigen, or PBS as a negative control, in the contra-lateral footpad. One series of mice additionally receives phosphate buffered saline (PBS)and Tween 0.5% i.p. at the initial sensitization, and at different dosing schedules thereafter, up until the Leishmania antigen challenge. A second series consists of groups of mice receiving different doses of the CCR4 antagonist(s) given either intra-peritoneally, intra-venously, sub-cutaneously, intra-muscularly, orally, or via any other mode of administration at the initial sensitization, and at different dosing schedules thereafter, up until the Leishmania antigen challenge. A third series of mice, serving as positive control, consists of groups treated with either mice IL-12, anti-IL4 antibodies i.p., or anti-IL5 antibodies i.p. at the initial sensitization, and at different dosing schedules thereafter, up until the Leishmania antigen challenge.
  • Over the next 48 hours, footpad swelling, caused by a Delayed-Type Hypersensitivity reaction to the Leishmania antigen challenge, is monitored with a metric caliper. The response of draining lymph node T cells to Leishmania antigen stimulation in vitro is also measured, both at the level of proliferation, cytokine production, and other phenotypic criteria. [0209]
    • EXAMPLE 26
  • This example describes a procedure to evaluate the efficacy of CCR4 antagonists for treatment of rheumatoid arthritis. [0210]
  • An animal model of rheumatoid arthritis can be induced in rodents by injecting them with type II collagen in selected adjuvants. Three series of rodent groups consisting 15 genetically-susceptible mice or rats per group are injected sub-cutaneously or intra-dermally with type II collagen emulsified in Complete Freund's Adjuvant at [0211] days 0 and 21. One series of rodents additionally receives phosphate buffered saline (PBS) and Tween 0.5% i.p. at the initial sensitization, and at different dosing schedules thereafter. A second series consists of groups of rodents receiving different doses of the CCR4 antagonist(s) given either intra-peritoneally, intravenously, sub-cutaneously, intra-muscularly, orally, or via any other mode of administration at the initial sensitization, and at different dosing schedules thereafter. A third series of rodents, serving as positive control, consists of groups treated with either mouse IL-10 i.p., or anti-TNF antibodies i.p.at the initial sensitization, and at different dosing schedules thereafter.
  • Animals are monitored from weeks 3 til 8 for the development of swollen joints or paws, and graded on a standard disease severity scale. Disease severity is confirmed by histological analysis of joints. [0212]
    • EXAMPLE 27
  • This example describes a procedure to evaluate efficacy of CCR4 antagonists for treatment of Systemic Lupus Erythematosus (SLE). [0213]
  • Female NZB/W F1 mice spontaneously develop an SLE-like pathology commencing at 6 months of age that is characterized by proteinuria, serum autoantibodies, glomerulonephritis, and eventually death. Three series of NZB/W mouse groups comprising 20 mice per group are tested for efficacy of CCR antagonist(s) as follows: One series of mice additionally receives phosphate buffered saline (PBS) and Tween 0.5% i.p. soon after weaning, and thereafter at varying dosing schedules. A second series consists of groups of mice receiving different doses of the CCR4 antagonist(s) given either intra-peritoneally, intra-venously, sub-cutaneously, intra-muscularly, orally, or via any other mode of administration soon after weaning, and thereafter at varying dosing schedules. A third series of mice, serving as positive control, consists of groups treated with anti-IL10 antibodies given soon after weaning, and thereafter at varying dosing schedules. [0214]
  • Disease development is monitored in terms of eventual mortality, kidney histology, serum autoantibody levels, and proteinuria. [0215]
    • EXAMPLE 28
  • This example describes a procedure to evaluate efficacy of CCR4 antagonists for treatment of malignancy. [0216]
  • SCID mice can be transplanted with primary human tumor cells. Normal mouse strains can be transplanted with a variety of well-characterized mouse tumor lines, including a mouse thymoma EL4 which has been transfected with OVA to allow easy evaluation of tumor specific antigen responses following vaccination with OVA. Three series of mouse groups from any of these tumor models are tested for CCR4 antagonist efficacy as follows: One series of mice additionally receives phosphate buffered saline (PBS) and Tween 0.5% i.p. soon after tumor transplant, and thereafter at varying dosing schedules. A second series consists of groups of mice receiving different doses of the CCR4 antagonist(s) given either intra-peritoneally, intra-venously, sub-cutaneously, intra-muscularly, orally, or via any other mode of administration soon after tumor transplant, and thereafter at varying dosing schedules. A third series of mice, serving as positive control, consists of groups treated with either anti-IL4 antibodies, anti-IFNg antibodies, IL4, or TNF, given i.p. soon after tumor transplant, and thereafter at varying dosing schedules. [0217]
  • Efficacy is monitored via tumor growth versus regression. In the case of the OVA-transfected EL4 thymoma model, cytolytic OVA-specific responses can be measured by stimulating draining lymph node cells with OVA in vitro, and measuring antigen-specific cytotoxicity at 72 hours. [0218]
    • EXAMPLE 29
  • This example describes procedures to evaluate the efficacy of CCR4 antagonists in psoriasis. [0219]
  • A rodent model of psoriasis can be obtained by intra-venously transferring a population of purified T cells (designated CD45Rbhi T cells) obtained from the spleens of BALB/c mice into immunodeficient recipient CB.17 scid/scid mice. Mice develop signs of redness, swelling, and skin lesions resembling those of human psoriasis in their ear, feet and tail by 8 weeks after transfer. Three series of mouse groups, comprising 10-15 CB.17 scid/scid mice per group, are injected with purified CD45Rbhi T cells. One series of mice additionally receives phosphate buffered saline (PBS) and Tween 0.5% i.p. at the initial cell transfer, and at different dosing schedules thereafter. A second series consists of groups of mice receiving different doses of the CCR4 antagonist(s) given either intra-peritoneally, intravenously, sub-cutaneously, intramuscularly, orally, or via any other mode of administration at the initial cell transfer, and at different dosing schedules thereafter. A third series of mice, serving as positive control, consists of groups treated with antibodies to either IL-12, IL-4, IFNg, or TNF, or with cytokine IL-10 at the initial cell transfer, and at different dosing schedules thereafter. Animals are monitored for development of psoriatic-like lesions for 3 months after cell transfer. [0220]
    • EXAMPLE 30
  • This example describes a procedure to evaluate the efficacy of CCR4 antagonists in Inflammatory Bowel Disease (IBD). [0221]
  • Several mouse models of IBD (including Crohn's Disease and Ulcerative Colitis) have been developed. Some of these are spontaneous models occurring in genetically engineered transgenic mice that have been depleted of certain cytokine genes (e.g. IL-10, or IL-2) by homologous recombination. Another mouse model of Inflammatory Bowel Disease is obtained by transferring highly purified populations of CD4+T lymphocytes bearing a particular surface marker phenotype (namely CD45 RB hi) into SCID mice. Three series of mouse groups from any one of these models can be used to evaluate CCR4 antagonist efficacy as follows. One group of mice additionally receives phosphate buffered saline (PBS) and Tween 0.5% i.p. soon after weaning in the case of the spontaneous models in transgenic mice, or at time of cell transfer into SCID mice and varying dosings thereafter for the cell transfer model. A second series consists of groups of mice receiving different doses of the CCR4 antagonist(s) given either intra-peritoneally, intra-venously, sub-cutaneously, intramuscularly, orally, or via any other mode of administration soon after weaning in the case of the spontaneous models in transgenic mice, or at time of cell transfer into SCID mice and varying dosings thereafter for the cell transfer model. A third series of mice, serving as positive control, consists of groups treated with antibodies to either IFNg, or TNF, or with cytokine IL-10 soon after weaning in the case of the spontaneous models in transgenic mice, or at time of cell transfer into SCID mice and varying dosings thereafter for the cell transfer model. [0222]
  • Mice are evaluated for 6-8 weeks for disease development, monitored initially via weight loss and/or prolapsed rectum, and eventually by histological evaluation of the animals colon and intestinal tract. [0223]
  • It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes. [0224]

Claims (84)

What is claimed is:
1. A method of treating a CCR4-mediated condition or disease in a subject, said method comprising administering to a subject in need of such treatment an effective amount of a compound having the formula:
Ar1-X-Ar2   (I)
wherein
Ar1 and Ar2 are each members independently selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted fused aryl-heterolcyclic ring systems and substituted or unsubstituted heteroaryl; and
X is a linking group selected from the group consisting of —N(R)—, —C(O)S—, —CH═CHSO2— and —SO2N(R)— wherein R is a member selected from the group consisting of H and substituted or unsubstituted (C1-C8)alkyl.
2. A method in accordance with claim 1, wherein X is —NH—.
3. A method in accordance with claim 1, wherein X is —SO2NH—.
4. A method in accordance with claim 1, wherein Ar1 and Ar2 are each substituted or unsubstituted members independently selected from the group consisting of:
Figure US20020173524A1-20021121-C00034
5. A method in accordance with claim 2, wherein Ar1 is substituted heteroaryl and Ar2 is substituted or unsubstituted aryl.
6. A method in accordance with claim 5, wherein said Ar1 is a substituted heteroaryl selected from the group consisting of substituted thiazolyl, substituted thienyl, and substituted furanyl.
7. A method in accordance with claim 5, wherein said Ar2 is a substituted or unsubstituted phenyl or a substituted or unsubstituted naphthyl.
8. A method in accordance with claim 3, wherein Ar2 is a phenyl group having from 1 to 4 substituents independently selected from the group consisting of halogen, hydroxy, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkylthio, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, nitro, cyano, (C1-C4)acyl, amino, (C1-C4)alkylamino, and di(C1-C4)alkyamino.
9. A method in accordance with claim 8, wherein said phenyl group has from 1 to 3 substituents independently selected from the group consisting of halogen, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, nitro, cyano, and (C1-C4)acyl.
10. A method in accordance with claim 3, wherein Ar1 is a substituted or unsubstituted monocyclic or bicyclic heterocycle.
11. A method in accordance with claim 10, wherein said heterocycle is selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidyl, benzothiazolyl, benzoxadiazolyl, purinyl, benzimidazolyl, indolyl, isoquinolyl, quinoxalinyl and quinolyl.
12. A method in accordance with claim 11, wherein said heterocycle is selected from the group consisting of thienyl, thiazolyl and benzoxadiazolyl.
13. A method in accordance with claim 1, wherein said CCR4-mediated condition or disease is selected from the group consisting of contact hypersensitivity, atopic dermatitis, allergic airway hypersensitivity, allergic rhinitis, atherosclerosis, septic shock, angina, myocardial infarction, restenosis, ischemia/reperfusion injury, multiple sclerosis, rheumatoid arthritis, type I diabetes, psoriasis, cancer and HIV infection.
14. A method in accordance with claim 1, wherein said CCR4-mediated condition or disease is psoriasis, contact hypersensitivity or atopic dermatitis.
15. A method in accordance with claim 14, wherein said CCR4-mediated condition or disease is psoriasis.
16. A method in accordance with claim 14, wherein said CCR4-mediated condition or disease is contact hypersensitivity.
17. A method in accordance with claim 14, wherein said CCR4-mediated condition or disease is atopic dermatitis.
18. A method in accordance with claim 1, wherein said CCR4-mediated condition or disease is a disease of the airway.
19. A method in accordance with claim 18, wherein said disease of the airway is selected from the group consisting of allergic asthma and allergic rhinitis.
20. A method in accordance with claim 18, wherein said disease of the airway is allergic asthma.
21. A method in accordance with claim 1, wherein said CCR4-mediated condition or disease is a disease of innate immunity.
22. A method in accordance with claim 21, wherein said disease of innate immunity is septic shock.
23. A method in accordance with claim 1, wherein said CCR4-mediated condition or disease is atherosclerosis.
24. A method in accordance with claim 1, wherein said CCR4-mediated condition or disease is a disease or condition characterized by platelet aggregation or thrombosis.
25. A method in accordance with claim 24, wherein said CCR4-mediated disease or condition is selected from the group consisting of angina, myocardial infarction, restenosis, stroke and ischemia/reperfusion injury.
26. A method in accordance with claim 1, wherein said CCR4-mediated condition or disease is an allergic condition and said compound is used alone or in combination with at least one therapeutic agent wherein said therapeutic agent is an antihistamine.
27. A method in accordance with claim 1, wherein said CCR4-mediated disease or condition is psoriasis and said compound is used alone or in combination with at least one therapeutic agent selected from a corticosteroid, a lubricant, a keratolytic agent, a vitamin D3 derivative, PUVA, or anthralin.
28. A method in accordance with claim 1, wherein said CCR4-mediated disease or condition is atopic dermatitis and said compound is used alone or in combination with at least one therapeutic agent selected from a lubricant and corticosteroid.
29. A method in accordance with claim 1, wherein said CCR4-mediated condition or disease is asthma and said compound is used alone or in combination with at least one therapeutic agent selected from a β2-agonist and a corticosteroid.
30. A method in accordance with claim 1, wherein said compound interferes with the interaction between CCR4 and a ligand.
31. A method in accordance with claim 1, wherein said administration is oral or intravenous.
32. A method in accordance with claim 1, wherein said subject is selected from the group consisting of human, rat, dog, cow, horse, and mouse.
33. A method in accordance with claim 1, wherein said subject is human.
34. A method in accordance with claim 1, wherein said compound is selected from the group consisting of
Figure US20020173524A1-20021121-C00035
35. A method in accordance with claim 1, wherein said CCR4-mediated disease or condition is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, type I diabetes, psoriasis, cancer and HIV infection; Ar1 is a substituted heterocycle; X is —SO2NH—; and Ar2 is a substituted phenyl.
36. A method in accordance with claim 1, wherein said CCR4-mediated disease or condition is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, type I diabetes, psoriasis, cancer and HIV infection; Ar1 is a substituted heterocycle; X is —NH—; and Ar2 is naphthyl.
37. A pharmaceutical composition for the treatment of a CCR4-mediated disease or condition, said composition comprising a pharmaceutically acceptable carrier and an effective amount of a compound which inhibits the binding of MDC or TARC to CCR4, said compound having the formula:
Ar1-X-Ar2   (I)
Ar1 and Ar2 are each members independently selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted fused aryl-heteocyclic ring systems and substituted or unsubstituted heteroaryl; and
X is a linking group selected from the group consisting of —N(R)—, —C(O)S—, —CH═CHSO2— and —SO2N(R)— wherein R is a member selected from the group consisting of H and substituted or unsubstituted (C1-C8)alkyl.
38. A composition of claim 37, wherein X is —NH—.
39. A composition of claim 37, wherein X is —SO2NH—.
40. A composition of claim 37, wherein Ar1 and Ar2 are each substituted or unsubstituted members independently selected from the group consisting of:
Figure US20020173524A1-20021121-C00036
41. A composition of claim 37, wherein Ar1 is substituted heteroaryl and Ar2 is substituted or unsubstituted aryl.
42. A composition of claim 41, wherein said Ar1 is a substituted heteroaryl selected from the group consisting of substituted thiazolyl, substituted thienyl, and substituted furanyl.
43. A composition of claim 41, wherein said Ar2 is a substituted or unsubstituted phenyl or a substituted or unsubstituted naphthyl.
44. A composition of claim 41, wherein Ar2 is a phenyl group having from 1 to 4 substituents independently selected from the group consisting of halogen, hydroxy, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkylthio, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, nitro, cyano, (C1-C4)acyl, amino, (C1-C4)alkylamino, and di(C1-C4)alkylamino.
45. A composition of claim 44, wherein said phenyl group has from 1 to 3 substituents independently selected from the group consisting of halogen, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, nitro, cyano, and (C1-C4)acyl.
46. A composition of claim 37, wherein Arl is a substituted or unsubstituted monocyclic or bicyclic heterocycle.
47. A composition of claim 46, wherein said heterocycle is selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidyl, benzothiazolyl, benzoxadiazolyl, purinyl, benzimidazolyl, indolyl, isoquinolyl, quinoxalinyl and quinolyl.
48. A composition of claim 47, wherein said heterocycle is selected from the group consisting of thienyl, thiazolyl and benzoxadiazolyl.
49. A composition of claim 37, wherein said compound is selected from the group consisting of
Figure US20020173524A1-20021121-C00037
50. A method for modulating CCR4 function in a cell, comprising contacting said cell with a CCR4-modulating amount of a composition of claim 37.
51. A method for modulating CCR4 function, in which said cell is contacted with a CCR4 protein with a therapeutically effective amount of the composition of claim 37.
52. A compound of formula (I):
Figure US20020173524A1-20021121-C00038
or a pharmaceutically acceptable salt thereof, wherein
W is selected from aryl, heteroaryl, (C1-C8)alkyl, heteroalkyl, cycloalkyl and heterocycloalkyl;
X is selected from N(R5), S, O, C(R3)═C(R4), N═C(R4) and, optionally, when Z is N, X can be C(R6)(R7);
Y is selected from a bond, N(R5), N(R5)—(C1-C8)alkylene, O, S and S(O)n, wherein the integer n is 1 or 2;
Z is selected from N and C(R8);
R1 and R2 are independently selected from H, halogen, CN, CO2R′, CONR′R″, (C1-C8)alkyl, heteroalkyl, aryl, heteroaryl, N(R6)(R7), OR9 and optionally, R1 and R2 combine to form a 5- to 8-membered ring containing from 0 to 3 heteroatoms selected from N, O and S, wherein R′ and R″ are independently selected from H, (C1-C8)alkyl and aryl, and when R′ and R″ are attached to nitrogen atom, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring;
R3, R4 and R8are independently selected from H, halogen, CN, OH, (C1-C8)alkyl, heteroalkyl, aryl, heteroaryl, O(C1-C8)alkyl, N(R6)(R7) and OR9;
R5 is selected from H, (C1-C8)alkyl, heteroalkyl, aryl and heteroaryl;
R6 and R7 are independently selected from H, (C1-C8)alkyl, heteroalkyl, aryl and heteroaryl; and
R9 is selected from (C1-C8)alkyl, heteroalkyl and haloalkyl;
with the provisos that R2 is other than H when W is unsubstituted phenyl, X is S, Y is NH, Z is N and R1 is (C1-C8)alkyl; and R1 is other than phenyl, when W is phenyl or unsubstituted naphthyl, X is S, Y is NH, and Z is N.
53. A compound of claim 52, wherein Z is N.
54. A compound of claim 52, wherein X is S.
55. A compound of claim 52, wherein Y is N(R5).
56. A compound of claim 52, wherein Z is N, X is S and Y is N(R5).
57. A compound of claim 52, wherein W is aryl or heteroaryl.
58. A compound of claim 57, wherein W is substituted or unsubstituted phenyl or naphthyl.
59. A compound of claim 57, wherein W is substituted or unsubstituted pyridyl or quinolyl.
60. A compound of claim 52, wherein R1 and R2 are each independently selected from H and (C1-C8)alkyl.
61. A compound of claim 52, wherein R1 and R2 are combined to form a fused 6-membered aryl or heteroaryl ring.
62. A compound of claim 52, wherein Z is N, X is S, Y is N(R5) and R1 and R2 are each independently selected from H and (C1-C8)alkyl.
63. A compound of claim 52, wherein Z is N, X is S, Y is N(R5) and R1 and R2 are combined to form a fused 6-membered aryl or heteroaryl ring.
64. A compound of claim 52, said compound being selected from the group consisting of:
Figure US20020173524A1-20021121-C00039
65. A compound of claim 52, said compound being selected from the group consisting of:
Figure US20020173524A1-20021121-C00040
66. A compound of claim 52, wherein
W is selected from substituted phenyl, substituted or unsubstituted naphthyl, pyridyl, quinolyl, (C1-C8)alkyl, heteroalkyl, cycloalkyl and heterocycloalkyl;
X is selected from N(R5), S, O, C(R3)═C(R4), N═C(R4) and, optionally, when Z is N, X can be C(R6)(R7);
Y is selected from a bond, N(R5), N(R5)—(C1-C8)alkylene, O, S and S(O)n, wherein the integer n is 1 or 2;
Z is selected from N and C(R8);
R1 and R2 are independently selected from H, halogen, CN, CO2R′, CONR′R″, (C1-C8)alkyl, heteroalkyl, aryl, heteroaryl, N(R6)(R7), OR9 and optionally, R1 and R2 combine to form a 5- to 8-membered ring containing from 0 to 3 heteroatoms selected from N, O and S, wherein R′ and R″ are independently selected from H, (C1-C8)alkyl and aryl, and when R′ and R″ are attached to a nitrogen atom, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring;
R3, R4 and R8are independently selected from H, halogen, CN, OH, (C1-C8)alkyl, heteroalkyl, aryl, heteroaryl, O(C1-C8)alkyl, N(R6)(R7) and OR9;
R5 is selected from H, (C1-C8)alkyl, heteroalkyl, aryl and heteroaryl;
R6 and R7 are independently selected from H, (C1-C8)alkyl, heteroalkyl, aryl and heteroaryl; and
R9 is selected from (C1-C8)alkyl, heteroalkyl and haloalkyl.
67. A compound of claim 66, wherein Z is N.
68. A compound of claim 66, wherein X is S.
69. A compound of claim 66, wherein Y is N(R5).
70. A compound of claim 66, wherein Z is N, X is S and Y is N(R5).
71. A compound of claim 66, wherein W is substituted phenyl or substituted or unsubstituted naphthyl.
72. A compound of claim 66, wherein W is substituted or unsubstituted pyridyl or substituted or unsubstituted quinolyl.
73. A compound of claim 66, wherein R1 and R2 are independently selected from the group consisting of H and (C1-C8)alkyl.
74. A compound of claim 66, wherein R and R2 are combined to form a fused 6-membered aryl or heteroaryl ring.
75. A compound of claim 66, wherein W is substituted phenyl or substituted or unsubstituted naphthyl, Z is N, X is S, Y is N(R 5), and R1 and R2 are independently selected from the group consisting of H and (C1-C8)alkyl.
76. A compound of claim 66, wherein W is substituted phenyl or substituted or unsubstituted naphthyl, Z is N, X is S, Y is N(R5), and R1 and R2 are combined to form a fused 6-membered aryl or heteroaryl ring.
77. A compound of claim 66, wherein W is substituted or unsubstituted pyridyl or substituted or unsubstituted quinolyl, Z is N, X is S, Y is N(R5), and R1 and R2 are independently selected from the group consisting of H and (C1-C8)alkyl.
78. A compound of claim 66, wherein W is substituted or unsubstituted pyridyl or substituted or unsubstituted quinolyl, Z is N, X is S, Y is N(R5), and R1 and R2 are combined to form a fused 6-membered aryl or heteroaryl ring.
79. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula (I):
Figure US20020173524A1-20021121-C00041
or a pharmaceutically acceptable salt thereof, wherein
W is selected from aryl, heteroaryl, (C1-C8)alkyl, heteroalkyl, cycloalkyl and heterocycloalkyl;
X is selected from N(R5), S, O, C(R3)═C(R4), N═C(R4) and, optionally, when Z is N, X can be C(R6)(R7);
Y is selected from a bond, N(R5), N(R5)—(C1-C8)alkylene, O, S and S(O)n, wherein the integer n is 1 or 2;
Z is selected from N and C(R8);
R1 and R2 are independently selected from H, halogen, CN, CO2R′, CONR′R″, (C1-C8)alkyl, heteroalkyl, aryl, heteroaryl, N(R6)(R7), OR9 and optionally, R1 and R2 combine to form a 5- to 8-membered ring containing from 0 to 3 heteroatoms selected from N, O and S, wherein R′ and R″ are independently selected from H, (C1-C8)alkyl and aryl, and when R′ and R″ are attached to nitrogen atom, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring;
R3, R4 and R8are independently selected from H, halogen, CN, OH, (C1-C8)alkyl, heteroalkyl, aryl, heteroaryl, O(C1-C8)alkyl, N(R6)(R7) and OR9;
R5 is selected from H, (C1-C8)alkyl, heteroalkyl, aryl and heteroaryl;
R6 and R7 are independently selected from H, (C1-C8)alkyl, heteroalkyl, aryl and heteroaryl; and
R9 is selected from (C1-C8)alkyl, heteroalkyl and haloalkyl.
80. A method for treating a CCR4-mediated condition in a subject, said method comprising administering to a subject in need of such treatment an effective amount of a compound of of formula (I):
Figure US20020173524A1-20021121-C00042
or a pharmaceutically acceptable salt thereof, wherein
W is selected from aryl, heteroaryl, (C1-C8)alkyl, heteroalkyl, cycloalkyl and heterocycloalkyl;
X is selected from N(R5), S, O, C(R3)═C(R4), N═C(R4) and, optionally, when Z is N, X can be C(R6)(R7);
Y is selected from a bond, N(R5), N(R5)—(C1-C8)alkylene, O, S and S(O)n, wherein the integer n is 1 or 2;
Z is selected from N and C(R8);
R1 and R2 are independently selected from H, halogen, CN, CO2R′, CONR′R″, (C1-C8)alkyl, heteroalkyl, aryl, heteroaryl, N(R6)(R7), OR9 and optionally, R1 and R2 combine to form a 5- to 8-membered ring containing from 0 to 3 heteroatoms selected from N, O and S, wherein R′ and R″ are independently selected from H, (C1-C8)alkyl and aryl, and when R′ and R″ are attached to nitrogen atom, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring;
R3, R4 and R8are independently selected from H, halogen, CN, OH, (C1-C8)alkyl, heteroalkyl, aryl, heteroaryl, O(C1-C8)alkyl, N(R6)(R7) and OR9;
R5 is selected from H, (C1-C8)alkyl, heteroalkyl, aryl and heteroaryl;
R6 and R7 are independently selected from H, (C1-C8)alkyl, heteroalkyl, aryl and heteroaryl; and
R9 is selected from (C1-C8)alkyl, heteroalkyl and haloalkyl.
81. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected from the group consisting of:
Figure US20020173524A1-20021121-C00043
82. A pharmaceutical composition of claim 81, wherein said compound is selected from the group consisting of:
Figure US20020173524A1-20021121-C00044
83. A method for treating a CCR4-mediated condition in a subject, said method comprising administering to a subject in need of such treatment an effective amount of a compound selected from the group consisting of:
Figure US20020173524A1-20021121-C00045
84. A method in accordance with claim 83, wherein said compound is selected from the group consisting of:
Figure US20020173524A1-20021121-C00046
US09/975,566 2000-10-11 2001-10-11 Modulation of CCR4 function Abandoned US20020173524A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/975,566 US20020173524A1 (en) 2000-10-11 2001-10-11 Modulation of CCR4 function
US10/654,112 US7262204B2 (en) 2000-10-11 2003-09-02 Modulation of CCR4 function

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24002200P 2000-10-11 2000-10-11
US29378101P 2001-05-23 2001-05-23
US09/975,566 US20020173524A1 (en) 2000-10-11 2001-10-11 Modulation of CCR4 function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/654,112 Division US7262204B2 (en) 2000-10-11 2003-09-02 Modulation of CCR4 function

Publications (1)

Publication Number Publication Date
US20020173524A1 true US20020173524A1 (en) 2002-11-21

Family

ID=26933078

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/975,566 Abandoned US20020173524A1 (en) 2000-10-11 2001-10-11 Modulation of CCR4 function
US10/654,112 Expired - Fee Related US7262204B2 (en) 2000-10-11 2003-09-02 Modulation of CCR4 function

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/654,112 Expired - Fee Related US7262204B2 (en) 2000-10-11 2003-09-02 Modulation of CCR4 function

Country Status (5)

Country Link
US (2) US20020173524A1 (en)
EP (1) EP1578341A2 (en)
AU (2) AU2002213467A1 (en)
CA (1) CA2425259A1 (en)
WO (1) WO2002030358A2 (en)

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030018022A1 (en) * 2001-05-23 2003-01-23 Tularik Inc. Ccr4 antagonists
US20040039035A1 (en) * 2000-10-11 2004-02-26 Tularik Inc. Modulation of CCR4 function
US20060079563A1 (en) * 1999-04-15 2006-04-13 Jagabandhu Das Cyclic protein tyrosine kinase inhibitors
US20060160880A1 (en) * 2003-12-23 2006-07-20 Jan Kehler 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI
US20060287386A1 (en) * 2005-06-17 2006-12-21 Jan Kehler Benzo[b]furane and benzo[b]thiophene derivatives
US20060287382A1 (en) * 2005-06-17 2006-12-21 Jan Kehler 2-(1H-indolylsulfanyl)-aryl amine derivatives
US20080027074A1 (en) * 2004-07-16 2008-01-31 Jan Kehler 2-(1H-Indolysulfanyl)-Aryl Amine Derivatives for Use in the Treatment of Affective Disorders, Pain, Adhd and Stress Urinary Incontinence
US20080275098A1 (en) * 2003-02-04 2008-11-06 Sanofi-Aventis Deutschland Gmbh Novel substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic aid
US20090312319A1 (en) * 2008-01-04 2009-12-17 Intellikine Certain chemical entities, compositions and methods
US20110046165A1 (en) * 2008-01-04 2011-02-24 Pingda Ren Certain chemical entitles, compositions and methods
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2013123320A1 (en) * 2012-02-15 2013-08-22 University Of Rochester Methods, pharmaceutical compositions, therapeutic systems, and compounds for treating b cell malignancies
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8642604B2 (en) 2006-04-04 2014-02-04 The Regents Of The University Of California Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US8785454B2 (en) 2009-05-07 2014-07-22 Intellikine Llc Heterocyclic compounds and uses thereof
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9321772B2 (en) 2011-09-02 2016-04-26 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US9629843B2 (en) 2008-07-08 2017-04-25 The Regents Of The University Of California MTOR modulators and uses thereof
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10131668B2 (en) 2012-09-26 2018-11-20 The Regents Of The University Of California Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2019090272A1 (en) 2017-11-06 2019-05-09 Flx Bio, Inc. Chemokine receptor modulators for treatment of epstein barr virus positive cancer
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10894797B2 (en) 2018-09-18 2021-01-19 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN112601526A (en) * 2018-08-29 2021-04-02 凯莫森特里克斯股份有限公司 Combination therapy using C-C chemokine receptor 4(CCR4) antagonists and one or more checkpoint inhibitors
US11110096B2 (en) 2014-04-16 2021-09-07 Infinity Pharmaceuticals, Inc. Combination therapies
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies
US12213983B2 (en) 2012-11-01 2025-02-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030008A1 (en) 2001-06-19 2003-01-22 Bristol Myers Squibb Co DUAL INHIBITORS OF PDE 7 AND PDE 4
EP2402309A1 (en) 2002-05-24 2012-01-04 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
US7049333B2 (en) 2002-06-04 2006-05-23 Sanofi-Aventis Deutschland Gmbh Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
EP1552842A1 (en) 2002-06-07 2005-07-13 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
PE20040693A1 (en) 2002-11-14 2004-11-23 Novartis Ag N-SULFONYLAMINOTIAZOLE AS MEDIATORS OF STEROID SULFATASE
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
KR100874292B1 (en) * 2002-11-18 2008-12-18 케모센트릭스 Aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
EP1661889A4 (en) * 2003-09-05 2009-08-05 Ono Pharmaceutical Co Chemokine receptor antagonist and medical use thereof
PL1667992T3 (en) 2003-09-19 2007-05-31 Astrazeneca Ab Quinazoline derivatives
TWI355894B (en) 2003-12-19 2012-01-11 Du Pont Herbicidal pyrimidines
DK1700856T3 (en) 2003-12-26 2015-12-14 Kyowa Hakko Kirin Co Ltd thiazole
KR20070011458A (en) 2004-04-08 2007-01-24 탈자진 인코포레이티드 Benzotriazine Inhibitors of Kinases
US20050282818A1 (en) * 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
BRPI0608810A2 (en) 2005-05-11 2010-01-26 Abbott Lab subtype 1 (vr1) vanilloid receptor antagonists and their uses
JP5251127B2 (en) 2005-10-28 2013-07-31 小野薬品工業株式会社 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF
JP5191391B2 (en) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド Bi-aryl meta-pyrimidine inhibitors of kinases
PL1961744T3 (en) 2005-11-18 2013-09-30 Ono Pharmaceutical Co Basic group-containing compound and use thereof
WO2007063935A1 (en) * 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation Aromatic compound
WO2007063934A1 (en) * 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation Alicyclic heterocyclic compound
WO2007132846A1 (en) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
JP5245827B2 (en) 2006-07-31 2013-07-24 小野薬品工業株式会社 Compound containing spiro-bonded cyclic group and use thereof
JP2008081492A (en) 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd Novel aminopyridine derivatives having selective inhibition of Aurora A
CN101622015A (en) 2007-03-05 2010-01-06 协和发酵麒麟株式会社 Pharmaceutical composition
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
WO2009042435A1 (en) 2007-09-21 2009-04-02 Array Biopharma Inc. Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
KR20100090250A (en) 2007-10-09 2010-08-13 메르크 파텐트 게엠베하 Pyridine derivatives useful as glucokinase activators
AR072297A1 (en) 2008-06-27 2010-08-18 Novartis Ag DERIVATIVES OF INDOL-2-IL-PIRIDIN-3-ILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE SYNTHESIS ALDOSTERONE.
EP2379076B1 (en) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
EP3241826B1 (en) 2009-02-25 2019-10-30 Takeda Pharmaceutical Company Limited Process for producing pyrrole compound
RU2561729C2 (en) 2009-07-08 2015-09-10 Дермира (Канада), Инк. Tofa analogues, applicable in treatment of dermatological disorders or conditions
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
US9246108B2 (en) 2012-12-28 2016-01-26 Dow Global Technologies Llc Quinoline-benzoxazole derived compounds for electronic films and devices
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
CN107266388A (en) * 2016-04-06 2017-10-20 重庆大学 A kind of aminothiazole analog derivative
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
DK3484528T3 (en) 2016-07-18 2021-02-15 Janssen Pharmaceutica Nv ROPE PET IMAGE FORMATION LIGANDER
ES2906078T3 (en) 2017-01-23 2022-04-13 Cadent Therapeutics Inc Potassium channel modulators
US10208052B1 (en) 2017-03-20 2019-02-19 Forma Therapeutics, Inc. Compositions for activating pyruvate kinase
EP3611256A1 (en) * 2018-08-14 2020-02-19 Universität Heidelberg Application of imidazopyridine derivatives in regenerative medicine
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
ES2989438T3 (en) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activation of pyruvate kinase R
EP3870291A1 (en) 2018-10-22 2021-09-01 Cadent Therapeutics, Inc. Crystalline forms of potassium channel modulators
WO2021055807A1 (en) 2019-09-19 2021-03-25 Forma Therapeutics, Inc. Activating pyruvate kinase r
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2863874A (en) * 1955-05-26 1958-12-09 Goodrich Co B F Process of preparing 2-aminothiazoles
US3467666A (en) * 1966-11-07 1969-09-16 Geigy Chem Corp 2-substituted aminothiazoles
US3896223A (en) * 1971-11-22 1975-07-22 Uniroyal Inc Anti-inflammatory thiazole compositions and methods for using same
US4275210A (en) * 1971-05-04 1981-06-23 Eli Lilly And Company Substituted 2-anilinobenzoxazoles
US4826990A (en) * 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US20030018022A1 (en) * 2001-05-23 2003-01-23 Tularik Inc. Ccr4 antagonists

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE603739A (en) * 1960-05-13
US3201409A (en) * 1961-04-24 1965-08-17 John D Spivack 2-substituted aminothiazoles
US6426360B1 (en) * 1994-07-28 2002-07-30 G D Searle & Co. 4,5-substituted imidazolyl compounds for the treatment of inflammation
KR100387658B1 (en) * 1996-04-12 2003-08-19 지.디. 썰 엘엘씨 Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
JPH10197825A (en) * 1997-01-10 1998-07-31 Sharp Corp Head mount type display
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
EP1003514A4 (en) 1997-07-25 2000-10-11 Merck & Co Inc Cyclic amine modulators of chemokine receptor activity
ATE413386T1 (en) * 1998-01-29 2008-11-15 Amgen Inc PPAR-GAMMA MODULATORS
CA2319781A1 (en) 1998-02-02 1999-08-05 Liping Wang Cyclic amine modulators of chemokine receptor activity
WO1999042455A1 (en) * 1998-02-19 1999-08-26 Tularik Inc. Antiviral agents
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6498161B1 (en) 1999-04-06 2002-12-24 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
EP1050307A1 (en) 1999-05-06 2000-11-08 Applied Research Systems ARS Holding N.V. CCR4 antagonists in sepsis
JP4739632B2 (en) * 2000-02-05 2011-08-03 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrazole compositions useful as inhibitors of ERK
WO2002034745A1 (en) 2000-09-15 2002-05-02 Anormed Inc. Chemokine receptor binding heterocyclic compounds
CA2425259A1 (en) 2000-10-11 2002-04-18 Tularik, Inc. Modulation of ccr4 function
CA2330350A1 (en) * 2000-12-05 2002-06-05 Chemokine Therapeutics Corporation Therapeutics for chemokine mediated diseases
WO2002094464A2 (en) 2001-05-22 2002-11-28 United Soil Recycling Method and system for remediating contaminated soil
CA2632618C (en) 2005-12-13 2014-04-22 Dekk-Tec, Inc. Demethylpenclomedine analogs and their use as anticancer agents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2863874A (en) * 1955-05-26 1958-12-09 Goodrich Co B F Process of preparing 2-aminothiazoles
US3467666A (en) * 1966-11-07 1969-09-16 Geigy Chem Corp 2-substituted aminothiazoles
US4275210A (en) * 1971-05-04 1981-06-23 Eli Lilly And Company Substituted 2-anilinobenzoxazoles
US3896223A (en) * 1971-11-22 1975-07-22 Uniroyal Inc Anti-inflammatory thiazole compositions and methods for using same
US4826990A (en) * 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US20030018022A1 (en) * 2001-05-23 2003-01-23 Tularik Inc. Ccr4 antagonists

Cited By (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060079563A1 (en) * 1999-04-15 2006-04-13 Jagabandhu Das Cyclic protein tyrosine kinase inhibitors
US8716323B2 (en) 1999-04-15 2014-05-06 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US8993567B2 (en) 1999-04-15 2015-03-31 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US9382219B2 (en) 1999-04-15 2016-07-05 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US20040039035A1 (en) * 2000-10-11 2004-02-26 Tularik Inc. Modulation of CCR4 function
US7262204B2 (en) 2000-10-11 2007-08-28 Amgen Inc. Modulation of CCR4 function
US20030018022A1 (en) * 2001-05-23 2003-01-23 Tularik Inc. Ccr4 antagonists
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
US20080275098A1 (en) * 2003-02-04 2008-11-06 Sanofi-Aventis Deutschland Gmbh Novel substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic aid
US7563908B2 (en) 2003-12-23 2009-07-21 Jan Kehler 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI
US7652150B2 (en) 2003-12-23 2010-01-26 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIs
US20080214645A1 (en) * 2003-12-23 2008-09-04 H. Lundbeck A/S Uses of 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssris
US20080176922A1 (en) * 2003-12-23 2008-07-24 H. Lundbeck A/S Uses of 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssris
US20060160880A1 (en) * 2003-12-23 2006-07-20 Jan Kehler 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI
US20080214644A1 (en) * 2003-12-23 2008-09-04 H. Lundbeck A/S 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri
US7737171B2 (en) 2003-12-23 2010-06-15 H. Lundbeck A/S Uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIS
US7737170B2 (en) 2003-12-23 2010-06-15 H. Lundbeck A/S Uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIS
US20080027074A1 (en) * 2004-07-16 2008-01-31 Jan Kehler 2-(1H-Indolysulfanyl)-Aryl Amine Derivatives for Use in the Treatment of Affective Disorders, Pain, Adhd and Stress Urinary Incontinence
US7678800B2 (en) 2004-07-16 2010-03-16 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives for use in the treatment of affective disorders, pain, ADHD and stress urinary incontinence
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
US20090192213A1 (en) * 2005-06-17 2009-07-30 H. Lundbeck A/S Benzo[b]furane And Benzo[b]thiophene Derivatives
US20060287382A1 (en) * 2005-06-17 2006-12-21 Jan Kehler 2-(1H-indolylsulfanyl)-aryl amine derivatives
US20060287386A1 (en) * 2005-06-17 2006-12-21 Jan Kehler Benzo[b]furane and benzo[b]thiophene derivatives
US7534791B2 (en) 2005-06-17 2009-05-19 H. Lundbeck A/S Benzo[b]furane and benzo[b]thiophene derivatives
US8642604B2 (en) 2006-04-04 2014-02-04 The Regents Of The University Of California Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents
US9493467B2 (en) 2006-04-04 2016-11-15 The Regents Of The University Of California PI3 kinase antagonists
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
US8785456B2 (en) 2008-01-04 2014-07-22 Intellikine Llc Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US9655892B2 (en) 2008-01-04 2017-05-23 Intellikine Llc Certain chemical entities, compositions and methods
US20090312319A1 (en) * 2008-01-04 2009-12-17 Intellikine Certain chemical entities, compositions and methods
US20110046165A1 (en) * 2008-01-04 2011-02-24 Pingda Ren Certain chemical entitles, compositions and methods
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US11433065B2 (en) 2008-01-04 2022-09-06 Intellikine Llc Certain chemical entities, compositions and methods
US9216982B2 (en) 2008-01-04 2015-12-22 Intellikine Llc Certain chemical entities, compositions and methods
US9822131B2 (en) 2008-01-04 2017-11-21 Intellikine Llc Certain chemical entities, compositions and methods
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US9637492B2 (en) 2008-03-14 2017-05-02 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US9629843B2 (en) 2008-07-08 2017-04-25 The Regents Of The University Of California MTOR modulators and uses thereof
US9828378B2 (en) 2008-07-08 2017-11-28 Intellikine Llc Kinase inhibitors and methods of use
US9790228B2 (en) 2008-09-26 2017-10-17 Intellikine Llc Heterocyclic kinase inhibitors
US9296742B2 (en) 2008-09-26 2016-03-29 Intellikine Llc Heterocyclic kinase inhibitors
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
US8785454B2 (en) 2009-05-07 2014-07-22 Intellikine Llc Heterocyclic compounds and uses thereof
US9315505B2 (en) 2009-05-07 2016-04-19 Intellikine Llc Heterocyclic compounds and uses thereof
US8569323B2 (en) 2009-07-15 2013-10-29 Intellikine, Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US9206182B2 (en) 2009-07-15 2015-12-08 Intellikine Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US9522146B2 (en) 2009-07-15 2016-12-20 Intellikine Llc Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
US9181221B2 (en) 2010-05-21 2015-11-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9738644B2 (en) 2010-05-21 2017-08-22 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9388183B2 (en) 2010-11-10 2016-07-12 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
USRE46621E1 (en) 2011-01-10 2017-12-05 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9840505B2 (en) 2011-01-10 2017-12-12 Infinity Pharmaceuticals, Inc. Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
US10550122B2 (en) 2011-01-10 2020-02-04 Infinity Pharmaceuticals, Inc. Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof
US9290497B2 (en) 2011-01-10 2016-03-22 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US11312718B2 (en) 2011-01-10 2022-04-26 Infinity Pharmaceuticals, Inc. Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9605003B2 (en) 2011-07-19 2017-03-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9718815B2 (en) 2011-07-19 2017-08-01 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9546180B2 (en) 2011-08-29 2017-01-17 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9115141B2 (en) 2011-08-29 2015-08-25 Infinity Pharmaceuticals, Inc. Substituted isoquinolinones and methods of treatment thereof
US9321772B2 (en) 2011-09-02 2016-04-26 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US9895373B2 (en) 2011-09-02 2018-02-20 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US9458123B2 (en) 2012-02-15 2016-10-04 University Of Rochester Methods, pharmaceutical compositions, therapeutic systems, and compounds for treating B cell malignancies
WO2013123320A1 (en) * 2012-02-15 2013-08-22 University Of Rochester Methods, pharmaceutical compositions, therapeutic systems, and compounds for treating b cell malignancies
US9255108B2 (en) 2012-04-10 2016-02-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9527847B2 (en) 2012-06-25 2016-12-27 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US11613544B2 (en) 2012-09-26 2023-03-28 The Regents Of The University Of California Substituted imidazo[1,5-a]pyrazines for modulation of IRE1
US10131668B2 (en) 2012-09-26 2018-11-20 The Regents Of The University Of California Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1
US10822340B2 (en) 2012-09-26 2020-11-03 The Regents Of The University Of California Substituted imidazolopyrazine compounds and methods of using same
US12213983B2 (en) 2012-11-01 2025-02-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US10329299B2 (en) 2013-10-04 2019-06-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9828377B2 (en) 2013-10-04 2017-11-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US12152032B2 (en) 2013-10-04 2024-11-26 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11541059B2 (en) 2014-03-19 2023-01-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10675286B2 (en) 2014-03-19 2020-06-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11944631B2 (en) 2014-04-16 2024-04-02 Infinity Pharmaceuticals, Inc. Combination therapies
US11110096B2 (en) 2014-04-16 2021-09-07 Infinity Pharmaceuticals, Inc. Combination therapies
US10941162B2 (en) 2014-10-03 2021-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10253047B2 (en) 2014-10-03 2019-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US11939333B2 (en) 2015-09-14 2024-03-26 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US11247995B2 (en) 2015-09-14 2022-02-15 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies
US11730736B2 (en) 2017-11-06 2023-08-22 Rapt Therapeutics, Inc. Anticancer agents
WO2019090272A1 (en) 2017-11-06 2019-05-09 Flx Bio, Inc. Chemokine receptor modulators for treatment of epstein barr virus positive cancer
CN112601526A (en) * 2018-08-29 2021-04-02 凯莫森特里克斯股份有限公司 Combination therapy using C-C chemokine receptor 4(CCR4) antagonists and one or more checkpoint inhibitors
US11518772B2 (en) 2018-09-18 2022-12-06 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US11459340B2 (en) 2018-09-18 2022-10-04 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
US11034705B2 (en) 2018-09-18 2021-06-15 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US10894797B2 (en) 2018-09-18 2021-01-19 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
US12264167B2 (en) 2018-09-18 2025-04-01 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors

Also Published As

Publication number Publication date
US20040039035A1 (en) 2004-02-26
US7262204B2 (en) 2007-08-28
WO2002030358A3 (en) 2009-06-11
EP1578341A4 (en) 2005-09-28
WO2002030358A2 (en) 2002-04-18
AU2002213467A8 (en) 2009-07-30
EP1578341A2 (en) 2005-09-28
CA2425259A1 (en) 2002-04-18
AU2002213467A1 (en) 2002-04-22

Similar Documents

Publication Publication Date Title
US7262204B2 (en) Modulation of CCR4 function
US7144903B2 (en) CCR4 antagonists
US7067662B2 (en) CXCR3 antagonists
US7053215B2 (en) Substituted Quinazolin-4(3H)-one compounds, compositions, and methods for their use
US6992084B2 (en) Compounds and methods for modulating CXCR3 function
US7799795B2 (en) Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders
US20070149557A1 (en) CXCR3 antagonists
US7939538B2 (en) Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
US7375102B2 (en) Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
AU2001297717A1 (en) CXCR3 antagonists
US20020132836A1 (en) Compounds and methods for modulating CCR4 function
US20040242498A1 (en) CXCR3 antagonists
US7271271B2 (en) Imidazolo-related compounds, compositions and methods for their use
US20110034487A1 (en) Cxcr3 antagonists
EP1743891A1 (en) Heterocyclic compounds and methods for modulating CXCR3 function

Legal Events

Date Code Title Description
AS Assignment

Owner name: TULARIK, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COLLINS, TASSIE;MAHMUD, HOSSEN;MEDINA, JULIO;AND OTHERS;REEL/FRAME:013520/0300;SIGNING DATES FROM 20020815 TO 20020825

Owner name: CHEMOCENTRYX, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MCMASTER, BRIAN;DAIRAGHI, DANIEL;SCHALL, THOMAS;REEL/FRAME:013553/0392;SIGNING DATES FROM 20020320 TO 20020416

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: ARROW ACQUISITION, LLC, CALIFORNIA

Free format text: MERGER;ASSIGNOR:TULARIK INC.;REEL/FRAME:016309/0003

Effective date: 20040813

Owner name: AMGEN SF, LLC, CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:ARROW ACQUISITION, LLC;REEL/FRAME:016309/0812

Effective date: 20040813

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载